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Heart failure is a chronic, progressive condition that affects over 6 million Americans. 
The gold standard treatment for advanced heart failure is heart transplant. However, when a 
donor heart is not available, or the patient is not eligible, patients may receive a mechanical 
circulatory support device such as a left ventricular assist device (LVAD).  
 
LVADs can improve patient survival and increase patient quality of life but they also 
require significant changes in lifestyle and carry with them risks of adverse events, such as re-
hospitalization, gastrointestinal bleeding (GI), stroke, or right heart failure. LVAD decision 
making for physicians and patients requires extensive discussion of the trade-off between 
benefits, risks, and associated lifestyle changes. Decision support tools for patients and their 
caregivers are in development but are not personalized and are limited to general educational 
information.  
 Using Bayesian modeling, a machine learning method of data analysis, I developed 
novel predictive models for three sets of LVAD outcomes: all-cause mortality, recurrent 
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gastrointestinal (GI) bleeding, and pump-dependent ischemic stroke. The mortality models 
performed better than current risk scores with receiver operating characteristic area under the 
curve (ROC AUC) of 70-71% in a multi-center validation cohort and 76-79% in a contemporary 
single-center study. The recurrent GI bleeding models performed with ROC AUCs of 68% and 
60%, revealed the importance of hemoglobin/hematocrit levels and inflammation in driving risk, 
and are the first models for this outcome. The ischemic stroke models out-performed the current 
ischemic risk score with ROC AUCs of 64-66%.  
 
In addition to model development, I explored how to present prognostic information to 
decision making stakeholders: physicians, patients, and caregivers. I accomplished this with 
three studies: pilot testing the usability of an online application for physicians, surveying 
potential LVAD patients’ interest in healthcare engagement, and comparing the interpretation of 
prognostic information in different visual formats between patients and the general population. 
The results of these studies indicated that survival predictions are the most important outcome in 
decision making; patient numeracy is a key determinant of decision making engagement; and use 
of line graphs to present prognostic information is well-suited to all stakeholders.  
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1.0  INTRODUCTION 
1.1 HEART FAILURE ETIOLOGY AND PROGRESSION 
Heart failure is a chronic, progressive condition that affects over 6 million Americans. It 
is characterized by a decline in function of the heart to pump enough blood to perfuse the body. 
To compensate for the loss of power, the heart may enlarge (cardiac dilation), the muscles of the 
heart may increase in mass, and/or the heart may pump faster. The vasculature may respond by 
narrowing blood vessels to increase overall pressure or diverting blood perfusion away from less 
important tissues. As the heart continues to under-perform, these compensation methods begin to 
fail. Symptoms resulting from heart failure are fatigue, shortness of breath, and difficulty 
moving. Patients with heart failure may not know they have the condition until the symptoms 
begin inferring with activities of daily living [1].  
To better describe and then treat heart failure, a system of classification is used called 
the New York Heart Association (NYHA) Functional Classification. There are four classes of 
patients, characterized by the functional capability of the patient from Class I – No limitation of 
physical activity, to Class IV – Unable to carry on any physical activity without discomfort, with 
symptoms present even when at rest [2].  
In early stages (Class I & II), heart failure can be managed with medication, reduced 
sodium diet, and exercise. However, these solutions do not solve the underlying issue of the 
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weakened heart and gradually become ineffective over time. When medication and lifestyle 
changes no longer are effective at managing symptoms, a patient is considered to have advanced 
heart failure (Class III & IV) [3].  
To further delineate the condition of advanced heart failure patients, the International 
Mechanical Circulatory Support registry (INTERMACS) classifies patients with end-stage HF 
into seven (7) profiles, with decreasing severity of illness [4]. The correlation between 
classification systems and their relationship to treatment modalities is presented in Figure 1 [5].  
 
Figure 1. Schematic of NYHA class and INTERMACs profile describing the heart failure treatment continuum [5]. 
Advanced heart failure treatments range from intravenous drug delivery (inotropes) to 
surgical interventions (cardiac resynchronization therapy, coronary artery bypass, percutaneous 
coronary intervention, valve repair or replacement, heart transplant) and device implantation 
(implantable cardioverter defibrillator, left and/or right ventricular assist device). At the end of 
the disease progression, palliative care and hospice are often considered. The tumultuous clinical 
course of disease progression and treatment intensity is depicted in Figure 2 [6].  
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Figure 2. Heart failure disease progression and treatment intensity [6]. 
The gold standard treatment for end-stage heart failure is a heart transplant. However, the 
number of hearts available for transplant is far less than the number of patients who need a new 
heart. Additionally, not all advanced heart failure patients are eligible for heart transplant, due to 
their age, comorbid conditions, or lifestyle choices. When a heart is not available, or the patient 
is not eligible, patients may receive a left ventricular assist device (LVAD).  
1.2 LEFT VENTRICULAR ASSIST DEVICES 
Originally just used as a bridge to transplant, the current generation of LVADs can also 
be used as a destination therapy for patients who are ineligible for transplant. LVADs can add 
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years to a patient’s life expectancy and increase quality of life [7, 8], but also require significant 
changes in daily life, investment of time and money, and present a heightened risk of severe 
adverse events [9].  
At the time of this writing, only two FDA approved continuous flow LVAD devices were 
commercially available in the United States: Heartmate II (Abbott) and HVAD (Medtronic) [10] 
(see Figure 3.) 
The Heartmate II was approved by the FDA in 2008 for bridge to transplant (BTT) and in 
2011 for destination therapy (DT) [11]. The HVAD was approved as BTT in 2012 and as a 
destination therapy in 2017 [12]. (The DT approval occurred after the last data collection for this 
study, and therefore is only used as BTT in the analyses presented herein.)  
Both devices are classified as continuous flow pumps. They are both implanted inside the 
body and are connected through the skin to an external controller and power system. The 
HeartMate II has an axial flow impeller and operates at 6000-15000 rotations per minute (rpm) 
to provide up to 10 liters per minute of blood flow. It is cannulated from the apex of the left 
ventricle, with outflow to the aorta. The HVAD is a centrifugal flow device that is cannulated 
directly to the left ventricular apex. It operates at 2000-5000 rpm to provide up to 10 liters per 
minute [13]. The HVAD design originally had a smooth titanium inflow cannula, but was 
updated with a sintered inflow cannula in 2011 due to the high rate of pump thrombosis and 
stroke [14].  
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Figure 3. Continuous flow LVADs currently in use: Heartmate II (A) and HVAD (B) [13] 
The driveline that exits the skin and the external controller require careful maintenance to 
avoid life-threatening infection or electrical failure. Both pumps are powered by AC power or 
batteries that plug into the controller. Therefore patients need to be near electrical outlets and/or 
carry extra charged batteries at all times [15]. In addition to maintaining the external hardware, 
patients are recommended to adhere to a low sodium diet. They also face increased risk of 
having to return to the hospital for pump-associated complications such as driveline infections, 
controller malfunction, pump thrombosis, or gastrointestinal bleeding [16]. Managing these life 
changes and risks not only demands the attention of the patient but the support of at least one 
dedicated caregiver [17].   
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Due to the trade-off of potentially improved survival and quality of life to change in 
lifestyle and risk of adverse events, the decision for a physician and patient to have an LVAD 
implanted requires careful review of educational information and discussion [6]. Accordingly, 
multidisciplinary heart failure teams must work together to educate patients and their caregivers 
on LVAD use, risks, and associated lifestyle changes as the patients are discerning their 
treatment options [18].  
1.2.1 Left Ventricular Assist Device Decision Making 
The decision to implant an LVAD is a daunting task for both patients and physicians; 
excess caution may deny a timely, life-saving intervention, but overzealous use may subject 
patients to significant morbidity, potentially diminishing their quality of life and/or hastening 
death. The complexity and challenge of clinical decision-making, therefore, lies in identifying 
the right patient who should receive an LVAD at the right time. 
Most patients that are referred for an LVAD implant are INTERMACS profile I & II. The 
morbidity and survival when implantation occurs at this point in disease progression is far from 
satisfactory and greatly impacts the financial and ethical ramifications of the procedure [7, 19]. If 
a referring physician could identify and refer patients who are both refractory to conventional 
therapy but not critically ill (INTERMACS 3 or higher), it is hypothesized that LVAD therapy 
may have a marked improvement in survival and quality of life outcomes [20].  
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The best practices for the use of an LVAD were recently published as a set of guidelines 
by The International Society for Heart and Lung Transplantation (ISHLT) [21] and the American 
Heart Association (AHA) [22]. While these guidelines are an essential first step toward 
implementation of this technology, they have fundamental limitations:  
(1) They are based on consensus and aggregated experience, and therefore cannot be 
personalized to an individual patient 
(2) They do not capture the values and needs of individual patients and their 
caregivers 
(3) They lack effective methods of communicating the risks and benefits of LVAD 
use to patients, which is essential to achieving shared decision making 
These limitations provide the motivation for the current research reported here. It is built 
on the premise that decision support tools are needed to augment the current guideline-based 
rationale for determining when and if to implant an LVAD in an advanced heart failure patient. 
1.3 FRAMEWORKS FOR DECISION SUPPORT TOOLS 
Requirements of an effective and safe clinical decision support tool have been a topic of 
much interest, particularly with the government incentive to establish and use electronic medical 
records [23]. For physicians, there is a clinical decision support guidance called the “Five Rights 
of CDS” (Table 1) [24]. For patients, there is the frequently updated and well-validated 
International Patient Decision Aid Standards (iPDAS) (Table 2) [25]. These two sets of 
guidelines define the frameworks to evaluate the existing tools for LVAD decision making.   
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Table 1. Five Rights of CDS [24] 
1. The right information, 
2. To the right person, 
3. In the right intervention format, 
4. Through the right channel, 
5. At the right time in workflow. 
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Table 2. iPDAS (v3) Checklist (excluding screening-specific requirements) 
Dimension / details Item 
Information 
Providing information about 
options in sufficient detail for 
making a specific decision 
1. The decision support technology describes the health condition or problem 
(intervention, procedure or investigation) for which the index decision is required 
2. The decision support technology describes the decision that needs to be 
considered (the index decision) 
3. The decision support technology describes the options available for the index 
decision 
4. The decision support technology describes the natural course of the health 
condition or problem, if no action is taken. 
5. The decision support technology describes the positive features (benefits or 
advantages) of each option 
6. The decision aid describes negative features (harms, side effects or 
disadvantages) of each option. 
7. The decision support technology makes it possible to compare the positive 
and negative features of the available options. 
8. The decision support technology shows the negative and positive features of 
options with equal detail (for example using similar fonts, order, and display of 
statistical information). 
Probabilities 
Presenting outcome 
probabilities 
1. The decision support technology provides information about outcome 
probabilities associated with the options (i.e. the likely consequences of decisions) 
2. The decision support technology specifies the defined group (reference class) 
of patients for which the outcome probabilities apply. 
3. The decision support technology specifies the event rates for the outcome 
probabilities (in natural frequencies). 
4. The decision support technology specifies the time period over which the 
outcome probabilities apply. 
5. The decision support technology allows the user to compare outcome 
probabilities across options using the same denominator and time period. 
6. The decision support technology provides information about the levels of 
uncertainty around event or outcome probabilities (e.g. by giving a range or by 
using phrases such as “our best estimate is…”) 
7. The decision support technology provides more than one way of viewing the 
probabilities (e.g. words, numbers, and diagrams). 
8. The decision support technology provides balanced information about event 
or outcome probabilities to limit framing biases. 
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Table 2 (continued). 
Clarifying and expressing 
values 
1. The decision support technology describes the features of options to help 
patients imagine what it is like to experience the physical effects. 
 2. The decision support technology describes the features of options to help 
patients imagine what it is like to experience the psychological effects. 
3. The decision support technology describes the features of options to help 
patients imagine what it is like to experience the social effects. 
4. The decision support technology asks patients to think about which positive 
and negative features of the options matter most to them. 
Decision Guidance 
Structured guidance in 
deliberation and 
communication 
1. The decision support technology provides a step-by-step way to make a 
decision. 
2. The decision support technology includes tools like worksheets or lists of 
questions to use when discussing options with a practitioner. 
Development 
Using a systematic 
development process 
1. The development process included finding out what clients or patients need to 
prepare them to discuss a specific decision 
2. The development process included finding out what health professionals need 
to prepare them to discuss a specific decision with patients 
3. The development process included expert review by clients/patients not 
involved in producing the decision support technology 
4. The development process included expert review by health professionals not 
involved in producing the decision aid. 
5. The decision support technology was field tested with patients who were 
facing the decision. 
6. The decision support technology was field tested with practitioners who 
counsel patients who face the decision. 
Evidence 1. The decision support technology (or associated documentation) provides 
citations to the studies selected. 
2. The decision support technology (or associated documentation) describes 
how research evidence was selected or synthesized. 
3. The decision support technology (or associated documentation) provides a 
production or publication date. 
4. The decision support technology (or associated documentation) provides 
information about the proposed update policy. 
5. The decision support technology (or associated documentation) describes the 
quality of the research evidence used. 
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Table 2 (continued). 
Disclosure and transparency 1. The decision support technology (or associated technical documentation) 
provides information about the funding used for development. 
2. The decision support technology includes author/developer credentials or 
qualifications. 
Plain Language 1. The decision support technology (or associated documentation) reports 
readability levels (using one or more of the available scales). 
DST Evaluation 1. There is evidence that the decision support technology improves the match 
between the features that matter most to the informed patient and the option that is 
chosen 
 
1.3.1 Physician-oriented Tools for LVAD Decision Making 
The primary decision support tools for physicians evaluating patients for LVAD implant 
are risk scores that predict post-operative mortality. The most commonly used scores are 
summarized in Table 3. Of these, only one risk score considers the format of delivery to 
physicians, the Seattle Heart Failure Model (SHFM), which has an online and downloadable 
calculator to present the risk of mortality at 1, 2, and 3 years. All other scores must be calculated 
by physicians on their own. Almost every risk score is derived from a small, clinical trial cohort, 
except the SFHM which was developed from a cohort of 1,125 ambulatory patients, who were 
less sick than the patients being considered for LVADs. Performance of these models can be 
good in their specific patient populations (ROC AUC 0.89 for DTRS) but does not maintain this 
rate of success with validation in the sickest patients, reflective of the current LVAD candidates 
(ROC AUC 0.58 for DTRS) [26].  
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Table 3. Physician-oriented tools for LVAD decision making 
Tool Outcome 
predicted 
Development 
cohort  
Validation 
cohort and 
performance 
Pro Con 
Heartmate II 
Risk Score [27] 
 
90-day and 1-
year mortality 
Derived from 
HMII BTT and 
DT trial patients 
(N = 1,122) 
randomly divided 
into derivation 
cohort 
(n = 583)  
 
Validation cohort 
(n = 539) 
 
AUC ROC: 0.64 
 
ROC AUC in 
LVAD patients 
from ROADMAP 
trial: 0.71 at 3 
months, 0.62 at 
12 months[28] 
Developed with 
contemporary 
device therapy 
era patients  
 
Discriminates 
survival in 
sicker, 
INTERMACS 
profiles 1-2, 
patients 
Performed less 
well than the 
MELD score 
(0.66) 
 
Did not 
discriminate well 
in the less sick. 
[29]  
Seattle Heart 
Failure Model 
(SHFM) [30] 
1-, 2-, and 3-
year mortality 
in patients 
with 
moderate HF 
Derived in a 
cohort of 1125 
ambulatory heart 
failure patients  
Prospectively 
validated in 5 
additional 
cohorts, n= 9,942 
ambulatory heart 
failure patients  
 
ROC AUC: 0.73 
 
ROC AUC in 
LVAD patients 
from ROADMAP 
trial: 0.71 
Applicable for 
both non-MCS 
and MCS patient 
cohort 
 
Easily accessible 
on the web 
 
Longest follow 
up of any 
prediction scores 
Validation cohort 
was not reflective 
of advanced HF 
population for 
whom MCS is 
being considered 
 
Overestimate 
survival when 
used to stratify 
advanced HF 
patients[31] 
Destination 
Therapy Risk 
Score 
90-day in-
hospital 
mortality for 
pulsatile DT 
LVADs 
Derived from 
patients 
consenting to be 
a part of the DT 
registry for the 
HeartMate XVE 
LVAD (n=222) 
Original 
validation ROC 
AUC: 0.89 
Good 
delineation 
between high 
and low risk 
groups in 1,124 
patients enrolled 
in the HMII DT 
and BTT trials  
Lacks 
applicability to 
the newer 
generation, CF-
LVADs devices  
 
ROC AUC: 0.54 
and 0.58 for the 
HeartMate II BTT 
and DT groups, 
respectively.[26] 
Model for End-
stage Liver 
Disease 
(MELD) for 
MCD[32] 
Correlated 
with bleeding 
risk and 
predicts 6-
month 
mortality 
Derived from 
n=231 patients 
being considered 
for transhepatic 
portosystemic 
shunts and later 
for liver 
transplant 
candidate 
categorization  
Bleeding 
validated in 
single center 
MCS population, 
n=211 
 
Mortality 
validated in 
INTERMACs 
registry, n=324 
 
In single center 
cohort, MELD 
predicted 
hospital stay,  
postoperative 
device 
infections, RV 
failure, and renal 
failure. 
 
In both cohorts, 
the MELD score 
was predictive 
of operative and 
6-month 
mortality. 
Limited utility in 
less ill cohort  
 
Not developed for 
MCS patients  
 
Does not include 
serum creatinine, 
which can 
indicate 
malnourishment 
and vastly 
underestimate 
renal dysfunction 
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1.3.2 Patient-oriented Tools for LVAD Decision Making 
There are two published patient decision support tools in development for LVAD 
patients, summarized in Table 4. Both tools are funded by grants from the Patient-Centered 
Outcomes Research Institute (PCORI). They both were developed using the guidelines from 
iPDAS, derived from single-center feedback and using multi-center clinical trials for validation. 
The results of both validation trials have not yet been published, so final outcomes in terms of 
benefit and impact of the tools are currently unknown. 
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Table 4. Patient-oriented tools for LVAD decision making 
Tool Development 
cohort 
Validation 
cohort  
Components Pro Con 
Colorado 
Patient 
Decision 
Support, 
PCORI [33] 
 
Semi-structured 
interviews with 
24 patients, 20 
caregivers, and 
24 clinicians to 
assess 
readability, bias, 
and usability 
 
DECIDE-
LVAD   clinical 
trial of 6 US 
hospitals, 
n=168 patient-
caregiver dyads 
Paper tool: 
educational 
information, 
pictographs of 
risks, self-directed 
patient values 
exercise, patient 
and caregiver 
perspectives 
  
Video 
Knowledge at 1 
month increased 
by 31% for 
patients and 6% 
for caregivers 
 
Values-treatment 
concordance at 1 
month 
was shown with 
both patients and 
caregivers, 
where treatment 
choice aligned 
with stated 
values  
 
Satisfied with the 
length of the 
decision aids 
Baseline study 
process for 
clinical trial as 
a whole 
was lengthy 
 
Video is 24 
minutes long 
without search 
or skip 
functionality 
Baylor, 
Deciding 
Together, 
PCORI [34] 
15 LVAD 
candidates, 15 
patients, 15 
caregivers, 15 
LVAD decliners 
and 11 clinicians 
involved in 
LVAD care were 
interviewed 
(n=71, total) 
Alpha tested 
through 
cognitive 
interviews 
(n=5) and 
acceptability 
tested with 
LVAD patients 
(n=10), 
candidates 
(n=10), and 
clinicians 
(n=13) 
 
Multi-site 
randomized 
trial across 5 
cardiovascular 
hospitals 
planned 
Paper tool, 
educational, risk 
information in 
pictographs, patient 
values exercise, 
patient narratives 
 
Video (online) 
Patients, 
caregivers and 
clinicians 
reported they 
would 
recommend the 
aid to patients 
considering 
treatment options 
for heart failure. 
1 hour to 
review entire 
decision aid 
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1.4 NEED FOR IMPROVED DECISION MAKING 
1.4.1 Physician support tools 
The current tools available for physicians only meet the first ‘right’ of the CDS 
framework. Their utilization for LVAD implant decision making is limited by the accessibility of 
the tool and the workflow habits of the decision-making team [35]. The amount of information 
required to be manually entered to calculate the risk scores (demographics, labs, history, family 
support, clinical parameters, etc.) further reduces the likelihood of use in real-time decision 
making. 
In this research thesis, I address the issues of model development with the right data 
(Aim 1) and presentation of the data in the right format and channel (Aim 2). Ongoing research 
by our colleagues addresses the right person to use the data and the right time in workflow the of 
support tool use [35].  
1.4.2 Patient support tools 
The risk information presented in current heart failure decision aids is limited to average 
probabilities for an aggregate population, for example, based on a clinical trial. However, recent 
utilization of machine learning and data mining, in combination with the growth of clinical data 
registries, has made it possible to develop patient-specific prognostic models. Our group has 
previously used these methods to develop personalized models for predicting LVAD outcomes, 
including mortality [36], recovery [37], and adverse events [38, 39].  
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Both tools currently in development for patients incorporate video or online components 
but use paper instruments for the primary education and have a patient self-guided response 
section. The response section is not used for analysis or shared with physicians but is intended to 
stimulate conversation with patients. There is no interactive component to the tools or feedback 
to the physician. 
This study aims to develop well validated predictive models with the latest clinical 
information and statistical techniques that can be shared with patients (Aim 1) and address their 
needs in an understandable and unbiased visual format (Aim 3). 
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2.0 AIM 1: BAYESIAN NETWORK MODELS 
The studies conducted in Aim 1 cover a range of modeling outcomes that demonstrate the 
versatility and utility of Bayesian networks to address the clinical decision making for LVADs. 
In Aim 1.1 outcomes for all-cause mortality are modeled for four different time points. 
This represents the most common outcome cited when physicians and patients discuss risks after 
LVAD implant. The use of multiple time points allows different factors that impact risk to be 
highlighted, from the pre-implant patient surgical history and end-organ function for early 
outcomes to patient age and frailty for longer-term outcomes. 
In Aim 1.2 the most commonly occurring adverse event is addressed: gastrointestinal 
(GI) bleeding. While GI bleeding is not associated with high patient mortality, it is closely 
related to the occurrence of other adverse events (e.g., re-hospitalization, infection, and stroke), 
and it significantly impacts quality of life. Recurrent GI bleeding is of the most concern to 
physicians, because it indicates inadequate medical management. In this aim, recurrent GI 
bleeding at any time after implant was modeled based on the patient pre-implant status and the 
patient status at the time of initial bleed. This is the first study to predict recurrent GI bleeding in 
this patient population. 
Finally, in Aim 1.3 the most pernicious adverse event for patients with and LVAD was 
addressed: ischemic stroke. Ischemic stroke risk is driven by the device-patient interaction, 
particularly the blood-material interface of the pump and the resulting change in hemodynamics. 
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To consider the important role pump design plays in effecting the risk of ischemic stroke, models 
were made to measure the risk of ischemic stroke for each pump type: axial and centrifugal. The 
latter analysis revealed different sets of predictive factors to be important for each pump type.  
The three predictive models developed in Aim 1 cover a spectrum of issues facing 
patients with LVADs and a range of data elements that can be used for model development with 
Bayesian networks.  
2.1 A BAYESIAN MODEL TO PREDICT MORTALITY FOLLOWING LEFT 
VENTRICULAR ASSIST DEVICE THERAPY 
2.1.1 Introduction 
Aim 1.1 sought to develop Bayesian-based prognostic models of mortality for multiple 
time points following implantation of a continuous flow LVAD, using the Interagency Registry 
for Mechanically Assisted Circulatory Support (INTERMACS). Although various risk 
stratification models to predict mortality post LVAD have been proposed over the years, they all 
have limited applications in ‘real life’ decision making [40], due to their derivation from small 
data sets, limited number of variables or isolated to a specific pump in a study population [41-
43]. Accurate predictions of outcomes after LVAD implantation depend on complex and 
dynamic interplay of multiple pre-operative variables that may not be captured by traditional 
multivariate modeling. Bayesian network (BN) modeling can account for dynamic, non-linear 
interactions between clinical and non-clinical variables and their influence on patient outcomes. 
In this way, they mimic complex human decision making, while drawing their diagnostic 
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algorithms from thousands of patients. Moreover, these models can predict outcomes at different 
time points post-LVAD by recognizing the time-varying importance of relevant variables. BN 
algorithms have been developed to predict mortality, gastrointestinal bleeding, and right 
ventricular failure in LVAD population [36, 39].  
2.1.2 Methods 
Patient cohort  
This study was approved by the INTERMACS Data, Access, Analysis, and Publication 
Committee. The Data Coordinating Center at University of Alabama at Birmingham provided 
de-identified patient data for implantations undertaken between April 2006 and December 2016 
(n=20,216). Modeling was performed using pre-implant patient information from January 2012-
December 2015, for adult (over 18 years of age) patients receiving a primary continuous flow 
LVAD or LVAD and right ventricular assist device (RVAD) in combination (n = 10,277). We 
chose this time frame to include current generation, continuous flow LVADs with least amount 
of missing data and derived from over 160 clinical sites in the United States [7]. Total artificial 
heart recipients and RVAD-only receipts were excluded from this study. Patients who received 
device exchanges (n=800) were included in the study, with total time on pump calculated across 
the multiple implants. Patients who recovered while on LVAD support or received heart 
transplants were included and indicated as “alive” in modeling outcomes up until that time point 
and censored for subsequent time points. Mortality post-LVAD implantation was noted at the 
following times: 1 month, 3 months, and 12 months.  
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Data pre-processing 
The INTERMACs data set includes over 400 pre-implant variables, with varying levels 
of data completion. BN construction requires no missing data in the training set. Therefore, 
preprocessing was required, in which the missing data elements were categorized into 2 sets: 
those missing in specific patterns (missing, not at random) and those that were ‘truly unknown’ 
(missing at random). An example of data missing, not at random, was if a patient did not 
complete a quality of life questionnaire because they were too sick, then the answers for all the 
questionnaire response variables were filled in as ‘not applicable’. A missing at random example 
was, if a patient did not perform a 6-minute walk test and no reason why was documented, then 
the result of that test (distance walked) was classified as missing rather than left blank. Variables 
with over 40% missing were excluded from the analysis (n=42). Additionally, variables with less 
than 1% positive responses (e.g., Previous Dor procedure, done in only 8 patients) were removed 
from the analysis (n=16).  
Some variables in INTERMACS capture information across a series of binary ‘Yes / No’ 
answers. To reduce the fields and improve the predictive power of variables, some fields were 
collapsed into multilevel variables. For example, INTERMACS has two variables for every 
comorbidity: Contraindication limiting transplant (Yes/No) and Contraindication, but not 
limiting transplant (Yes/No). These were collapsed into Contraindication: Yes, Yes-limiting 
transplant, or No. In this way, the number of variables for modeling was reduced. Fields for past 
medical interventions were combined into total counts of events, while keeping the individual 
binary information. For example, a patient with a coronary artery bypass grafting (CABG) and 
dialysis during their hospitalization was captured as CABG- Yes, Dialysis- Yes, and Total Event 
Count- Two. Variables with many levels were broken into subsets to identify important features. 
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For instance, Primary Diagnosis (a 31-level variable) was divided in to Ischemic Etiology, 
Restrictive Myopathy, Dilated Myopathy, and Congenital disease. After variable pre-processing, 
203 pre-implant variables were used in the model construction.  
Modeling cohorts 
BN classifiers were derived for each time point of interest using a training dataset 
consisting of 80% of the data records selected at random (using Weka test/train split function.) 
The remaining 20% of data was held aside as the test set for the final model validation. This 
resulted in 6 sets of data across 3 pre-specified time points, three training sets—one for each 
model—and three test sets. The three training sets were each processed for feature selection 
independently. 
Discretization of Continuous Variables 
Bayesian modeling requires that all variables be categorical, therefore continuous 
variables must be discretized. In this study, four different methods of discretization were 
explored: expert binning (cut points determined for VAD implant guidelines, established risk 
tools, and normal ranges), supervised binning (MDL method in Weka), equal frequency binning, 
and equal width binning. Using training data, information gain was measured for each variable 
using each method, and results were compared. Choosing the method that yielded the highest 
information gain for each variable, a hybrid approach of expert binning, equal frequency, and 
equal width binning was used in to discretize the variables. This was performed for all 3 models. 
 
 
 
 
 22 
Feature selection 
To select variables for inclusion in the model, information gain was run in a 10-fold cross 
validation on the training data, with the recurring top variables being selected for model 
inclusion. Cut off for selection was information gain > 0.003 for all three time points. This 
resulted in a set of 29, 26, and 31 variables for the 1, 3, and 12-month models, respectively.  
Bayesian Analysis   
BNs process individual patient data in a dynamic and non-linear fashion to predict 
probable outcomes. The selected features from the training sets were used to learn both Tree 
Augmented Naïve Bayes (TAN) and Naïve Bayes (NB) graphical models using GeNie software 
(BayesFusion, Pittsburgh, PA). Each model was optimized by running 10-fold cross validation 
and removing or adding variables that either had low diagnostic value (as calculated in GeNie) or 
were on the cusp of the information gain cut off. At all three time points the NB models had 
superior performance, as measured by the area under the receiver operator characteristics curve 
(ROC AUC). The final NB models had 28, 26, and 21 predictive variables for the 1, 3, and 12-
month models, respectively. Variables were grouped into three categories: demographics/patient 
status, medical history, and test results (laboratory, exercise and imaging). 
Final Validation 
Models were validated using the three test sets, which had not been used in the prior 
model learning. ROCs were plotted in R. In addition, we also report accuracy, sensitivity, and 
specificity (assuming a 50% threshold) of the Bayesian models’ performance. 
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2.1.3 Results 
A total of 10,277 patients met the inclusion criteria (Figure 4). The majority were 
between 50 and 69 years of age (n = 6,174; 60%); 78% (n = 8,044) were male; 3,811 patients 
(35%) received the LVAD as DT, and 5,528 patients (54%) were listed as BTT. Ischemic disease 
was listed as the cause for cardiomyopathy in 4,637 patients (41=5%). At the time of 
implantation, 16% (n = 1,671) were categorized as INTERMACS profile 1, 35% (n = 3,548) as 
INTERMACS profile 2, and 32% (n = 3,318) as INTERMACS profile 3. In the training sets (n = 
8,222), 1-month mortality was 5% (n = 426), 3-month mortality was 9% (n = 776), and 12-
month mortality was 18% (n = 1459). In the test sets (n = 2,055), mortality was at 6% (n = 114) 
at 1-month, 10% (n = 200) at 3-month, and 19% (n = 390) at 12-month post LVAD implantation. 
 
 
Figure 4. Model cohort selection 
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Models and test validation:  
Bayesian models for 1, 3, and 12 months post-LVAD are illustrated in Figures 6,7, and 8. 
Variables are color-coded according to 3 categories: demographics/patient status, medical history 
and results. ROCs, accuracy, sensitivity, specificity, and AUC ROC are summarized in Figure 5 
and Table 5. Accuracy ranged between 76% and 87%, and ROC AUC ranged between 70% and 
71%. 
 
Table 5. Model test validation performance 
 1-month 3-month 12-month 
Accuracy 87% 82% 76% 
Sensitivity 30% 33% 33% 
Specificity 90% 87% 86% 
ROC AUC 70% 71% 70% 
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Figure 5. ROC curves for Bayesian models to predict various time points post LVAD implantation (0.70 at 
1 month, 0.71 at 3 months, 0.70 at 12 months) 
 
Mortality at 1-month post LVAD: This NB model contains 28 variables directly 
connected to the outcome (Figure 6). Although the order of influence changes as variables are 
observed or specified (i.e., while calculating the risk for a specific patient), the variables most 
predictive of early post-LVAD mortality are concomitant RVAD implant, total number of events 
during the implant hospitalization, low platelet count, high bilirubin levels, high aspartate 
aminotransferase (AST) level, and low INTERMACS profile. 
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Figure 6. Bayesian model for predicting mortality 1-month post LVAD implantation. Variables are color 
 coded: demographics (yellow), medical history (orange) and test results (blue). 
 
Mortality at 3 months post LVAD: The NB model for mortality at 3 months post LVAD 
had 26 variables, with concomitant RVAD implant, older age, elevated blood urea nitrogen, low 
hemoglobin and lower INTERMACS profiles being highly predictive of higher mortality risk 
(Figure 7). 
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Figure 7. Bayesian model for predicting mortality 3 months post LVAD implantation 
 
Mortality at 12 months post LVAD: The NB model for mortality at 12 months post 
LVAD had 12 variables, with older age, elevated blood urea nitrogen, low hemoglobin, DT 
device strategy, and concomitant RVAD implant being highly predictive of mortality (Figure 8). 
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Figure 8. Bayesian model for predicting mortality 12 months post LVAD implantation 
 
Unique variables across time points: 
There were several variables that impacted risk of mortality across all time points such as 
old age, dialysis during index hospitalization, previous cardiac operations, albumin, platelet 
count, blood urea nitrogen. Similarly, there were several highly predictive variables that 
predicted short term mortality which were distinct from those predicting 12-month risk of death. 
These included lower INTERMACS profile, pre-operative ventilator dependence and hepatic 
function (indicated by AST and bilirubin levels) affecting 1-month mortality while ischemic 
etiology, history of chronic renal disease and frailty contributed more to 12-month mortality. 
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2.1.4 Discussion 
Appropriate patient selection is key to optimal outcomes after LVAD therapy. There is a 
critical need for an accurate predictive model that is derived from a comprehensive database 
across multiple clinical sites, incorporates the impact of a large variety of clinical variables to 
account for the heterogeneity of end stage HF patient, and is up to date with the evolving 
technologic innovation in mechanical circulatory support devices. In other words, a successful 
predictive tool would mimic human decision making, while drawing on data from tens of 
thousands of patients who have undergone LVAD implantation. BN algorithms can provide the 
necessary tools to achieve this, as demonstrated in our analysis.  
These analyses revealed a variety of risk factors from disparate categories (e.g., 
demographics, medical history, and laboratory test results) that influence post LVAD survival. 
Many of the variables that were found to be predictive in these models have previously been 
recognized as high risk factors in separate analysis [27, 44, 45]. Rather than trying to combine a 
multiplicity of factors by using a weighted summation, Bayesian models provide a dynamic 
incorporation of many variables, yielding a more robust ROC value than previously published 
scores [46]. The 90-day and 12-month HMRS stratifications had AUC of 60% and 57%, 
respectively [27], whereas the Bayesian 90-day and 12-month predictions exhibited AUC of 71% 
and 70%, respectively. BN analyses can show how clinical variables impact the predicted class 
value (mortality) without requiring that every patient variable be entered to give a prediction. 
This is an advantage over existing risk scores, which are rendered unusable if any of the 
parameters are not known. 
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In the present analysis, there were several variables found to have significant impact on 
the predicted mortality at different time points after LVAD implantation. These included 
clinical and non-clinical variables, both of which play a vital role in decision-making that occurs 
on a day-to-day basis with these often critically ill patients. An example of a non-patient variable 
was the number of LVAD implants performed at a site annually, which has been shown to 
impact outcomes [27]. The final BN models included both non-modifiable/historical variables 
(such as patient age and surgical intervention history) and modifiable variables (such as 
nutritional assessment and renal function). Long-term mortality post-LVAD implant is likely 
more influenced by post-operative adverse events (such as stroke, infections, or right ventricular 
failure) than pre-operative variables, which is reflected by a slight drop in the ROC for the 12-
month mortality model. 
The ability to recognize the impact of different variables in predicting mortality at 
various time points post-LVAD implant is important, given that many high-risk variables (e.g. 
acute renal failure) that could impact short term mortality may reverse with time and be less 
relevant in predicting long term outcomes [47]. Although there are some high-risk variables that 
impact both short and long-term risk of mortality, their depth of impact may change over time. 
Extrapolating data from 90-day models to predict one-year mortality as was done in HeartMate 
Risk Score (HMRS) neglects this change in variable importance, but is overcome by using 
multiple, independent predictive models. 
These BN mortality models demonstrated a remarkable improvement over existing 
models with respect to accuracy, specificity and ROC. The models in this study have an ability to 
(1) learn from prior probability, (2) apply to the most recent patient mix and device technology, 
and (3) be more tolerant to missing data elements when calculating predictions. In addition, BNs 
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reflect the natural clinical decision-making process as compared to traditional risk scores and 
therefore provide greater confidence as a tool for those making medical decisions. 
Limitations: 
We acknowledge that this study has several important limitations, including missing data 
pertaining to the independent variables. Although the INTERMACS database is large and 
representative, it suffers from sparsity of many data elements. This prompted us to exclude some 
variables which may have been relevant predictors. Additional limitations include inherent 
retrospective bias (all patients were already chosen to receive an LVAD) and only FDA 
approved VAD devices were included in registry. However, despite these limitations, our study 
does not suffer from other, more common limitations (e.g., single centered) as we utilized the 
most comprehensive and robust registry currently available for LVAD recipients. 
2.1.5 Conclusion 
The BN mortality models show great promise as reliable and accurate risk stratification 
tools for clinical decision making. The potential utility of the models is to assist the medical team 
in decision making with patients for whom the merits or contraindications to LVAD implantation 
are not immediately clinically apparent. Accordingly, we hope that CORA will promote the 
appropriate and perhaps judicious use of LVAD therapy by providing clinicians and patients a 
more informed decision regarding potential short-term and long-term outcomes. 
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2.2 PREDICTING PREDISPOSITION TO AND RECURRENCE OF GI BLEEDING 
IN PATIENTS WITH CF-LVADS 
2.2.1 Introduction 
Gastrointestinal (GI) bleeding is one of the most frequently occurring adverse events in 
patients who have continuous flow left ventricular assist devices (CF-LVADs), with an incidence 
reported between 18% and 40% [48, 49]. Typically recurrent, it substantially impacts the 
patient’s quality of life through frequent readmissions, prolonged hospitalizations [50], and a 
potentially higher risk of infection and thromboembolic events [51]. In addition, the associated 
blood transfusions may result in allosensitization [52] which impacts the patient’s transplant 
candidacy[53, 54] and can pose a long term risk of post-transplant rejection.  
The etiology of GI bleeding in patients with CF-LVADs has been studied extensively and 
is likely multifactorial. Non-pulsatile blood flow [55], which may lead to vascular stiffening [56, 
57] or arteriovenous malformation (AVM)[58], unfolding of von Willebrand factor from the 
shear stress of the impeller that leads to increased susceptibility to degradation and an acquired 
von Willebrand syndrome [59], elevated Angiopoeitin-2 levels due to coagulation factors from 
blood-metal interface leading to AVM [60], and the need for anticoagulation and antiplatelet 
therapy[61] have all been associated with elevated risk of GI bleeding.  
Pre-implant clinical risk factors that are known to be associated with increased incidence 
of GI bleeding include older age, elevated creatinine, and pre-operative right heart failure [52, 
57]. Given the heterogeneity of GI bleeding etiology and the effect of both pre- and post-LVAD 
implant factors, multivariate modeling or focusing on pre-implant variables alone may not be 
adequate for identifying patients who are at risk for GI bleeding. There is a need to better 
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understand the factors that impact the risk of GI bleeding, which may provide insights as to how 
GI bleeding may be mitigated or prevented. In this study, we use Bayesian network modeling on 
a large, retrospective data set to construct two predictive models to better characterize the risk 
factors and causes for GI bleeding (Figure 9).  
2.2.2 Methods 
Data Source 
The data for this study was derived from the Interagency Registry for Mechanical 
Assisted Circulatory Support (INTERMACS), funded by the National Heart, Lung and Blood 
Institute, National Institutes of Health, Department of Health and Human Services. 
Inclusion criteria for this study were the use of a CF-LVAD as the primary implant 
between years 2010 and 2015 in patients over 18 years old. Patients who received biventricular 
ventricular assist devices (BiVADs) were included. Patients with temporary RVAD support 
alone were excluded. Total artificial heart implants and pulsatile LVAD implants were excluded. 
Patients were excluded from the model if they died or were transplanted within the first 30 days 
of implant.  
Endpoints 
Incidence of GI bleeding was determined using INTERMACS event data and definitions. 
A GI bleeding event was identified as an upper GI bleed, lower GI bleed, or positive occult stool 
(location unknown). To assess GI bleeding that was caused by the LVAD implant, initial GI 
bleeding was defined as a GI bleeding event occurring more than 2 weeks after implant. GI 
bleeding events occurring before 2 weeks were not counted. Recurrent GI bleeding was 
identified as an additional GI bleeding event occurring 2 or more weeks after the initial bleed. 
 34 
This outcome is used as the study endpoint because a patient with a single GI bleeding event 
with no recurrence can be considered effectively managed and the GI bleed is less likely to be 
LVAD related. Specifically, our goal is to address CF-LVAD-associated reasons for GI bleed, 
which may result from the chronic dis-regulated angiogenic state that leads to multiple bleeds. 
Focusing on recurrent GI bleeding allows for prediction of successful (non-hemorrhagic or non-
recurring) versus unsuccessful (recurrent GI bleeding) outcomes. There was no maximum time 
limit set between initial and recurrent bleeding events.  
 Model scope 
Two models to predict recurrent GI bleeding were constructed in this study (Figure 9.) 
The first model used patient pre-implant health information to predict the risk of recurrent GI 
bleeding after CF-LVAD implantation. The pre-implant predisposition model used mostly non-
modifiable patient characteristics. The modeling data set included 13,082 patients, with 1,439 
(11%) having recurrent GI bleeding.  
The second model used post-operative factors at the time of a patient’s first GI bleeding 
event to predict the risk of a second GI bleeding event. This is referred to as the post-implant risk 
model for recurrent GI bleeding events. The goal of this model was to provide insight on the 
LVAD-related factors associated with recurrent bleeding. The model used medications at the 
time of the initial GI bleeding event (e.g., anticoagulation), labs (e.g., INR) and therapeutic 
interventions within one week of the initial GI bleeding event. Of the 3,139 patients with a single 
GI bleeding event at least two weeks after CF-LVAD implant, patients without data within a 
one-week window of their initial bleed were excluded (n= 1,612). The remaining 1,527 patients 
were used in the post-implant risk model building, with 49% having a recurrent GI bleed. 
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Model development and validation 
INTERMACS data was processed by discretizing continuous variables using the 
supervised binning class-attribute interdependence maximization (CAIM) method, which was 
iterated 5 times[62]. Missing data was not imputed but was captured categorically as “missing”.  
Feature selection was performed using information gain and hill climbing, each with 10-
fold iterations, to select the primary variables impacting recurrent GI bleeding. After creating a 
subset of variables using information gain (gain > 0.003) and the most frequently selected 
variables from hill climbing, a Tree Augmented Naïve (TAN) Bayes model was created and 
validated by 10-fold cross validation using GeNie software (BayesFusion, Pittsburgh, PA). 
Variables in the model were evaluated for their impact on the prediction by diagnostic value. 
Diagnostic value is a measure of the influence the variable has on the model prediction, based on 
the expected gain in cross-entropy. Variables with the lowest diagnostic value were removed 
from feature selection and the model was re-learned and validated with 10-fold cross validation. 
Variables were iteratively removed and added until the model performance, defined by the 
receiver operating characteristic area under the curve (ROC AUC), no longer improved. 
Model validation was performed using more recent patient data from INTERMACS, 
covering new implants done in 2015-2016, as well as data from previous patients who had not 
experienced recurrent bleeding by 2015 and who were still alive on their original CF-LVAD. 
The pre-implant predisposition model had 3,351 patients and the post-implant risk model had 
1,236 patients in the validation cohorts. 
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Figure 9. Schematic of Patient Selection for Models.  
2.2.3 Results 
Incidence of GI Bleeding 
Of the 13,082 patients implanted with a primary CF-LVAD between 2010 and 2015, 
3,505 patients (27%) had 7,426 episodes of GI bleeding. The mean number of GI bleeding events 
per patient was 2.1 with a range of 1 to 45 per patient. GI bleeding events were experienced by 
patients from 0.5 to 64 months after implant, with the mean time to the first GI bleeding event of 
6.6 months and median time of 2.4 months. The mean time between the first and second GI bleed 
was 4.3 months and median time of 1.7 months (range 0.5 to 61 months).  
Pre-implant characteristics of patients with and without recurrent GI Bleeding 
Of the 13,082 patients, 1,439 (11%) experienced recurrent GI bleeding. Compared to the 
non-recurrent bleeding cohort (patients with 0 or 1 GI bleeding event), patients who had 
recurrent GI bleeding events were more likely to be older (age 60-79), on an axial flow pump 
(HeartMate II), and implanted as a destination therapy (Table 6).  
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Table 6. Clinical Characteristics of Patients by GI Bleeding Recurrence 
Patient Information Non-Recurrent GI 
Bleeding (0-1 
events),  
n = 11,643 
Recurrent GI 
Bleeding (2+ 
events),  
n = 1439 
  
  n % n % p-value 
Pump Type Centrifugal 2069 18% 140 10% < 0.001 
  Axial 9572 82% 1299 90% < 0.001 
Device  LVAD 11320 97% 1413 98% 0.032 
  BiVAD 323 3% 26 2% 0.032 
NYHA Class  III 2112 18% 245 17% 0.298 
  IV 8608 74% 1085 75% 0.230 
Strategy DT 4803 41% 829 58% < 0.001 
  BTT 6749 58% 600 42% < 0.001 
Age 80+ 75 1% 14 1% 0.153 
  70-79 1450 12% 307 21% <0.001 
  60-69 3613 31% 651 45% <0.001 
  50-59 3243 28% 354 25% 0.009 
  40-49 1734 15% 89 6% <0.001 
  30-39 952 8% 21 1% <0.001 
  19-29 576 5% 3 0% <0.001 
Gender Male 9152 79% 1121 78% 0.542 
 
Data shown as the total in each category and percentage of total, with comparison 
between groups measured using a two-way z-test. Acronyms: LVAD, Left Ventricular Assist 
Device; RVAD, Right Ventricular Assist Device; DT, Destination Therapy; BTT, Bridge to 
Transplant (includes patients listed and not-yet listed). In this dataset, all axial flow pumps are 
Heartmate II (Abbott) and all centrifugal flow pumps are HVAD (Medtronic). 
 
Recurrent GI bleeding Predisposition Model and Results 
Out of 261 pre-implant variables that were used in feature selection, 18 were identified as 
the top predictors of predisposition for recurrent GI bleeding (Figure 10). Final cross-fold 
validation ROC AUC was 69% (Figure 11). In the validation data set from INTERMACS 
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(n=3,351 patients), 13% of patients experienced recurrent GI bleeding events. Model 
performance with this test data was ROC AUC of 68% (Figure 11). 
 
 
Figure 10. Predisposition to Recurrent GI Bleeding Model. Arrows indicate a relationship between 
variables, with arrow thickness indicating strength of relationship. 
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Figure 11. Receiver operating characteristic curves for predisposition to GI bleeding events, by cross-fold 
and test validation 
 
The most predictive variables driving recurrent GI bleeding risk were: age, previous 
cardiac operations, anemia (low hemoglobin), destination therapy device strategy, axial flow 
pump, and elevated blood urea nitrogen (BUN). A summary of all the variables, their diagnostic 
value, and effect on risk is captured in Table 7. 
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Table 7. Summary of Variables Predicting Predisposition to Recurrent GI Bleeding 
Variable Diagnostic 
Value 
Increase or Decrease Risk 
Age 0.05 Increase with age 
Device strategy 0.019 Increase when DT 
Previous CABG 0.018 Increase 
Previous Cardiac Operations 0.016 Increase 
Advanced Age 0.014 Increase 
Hemoglobin (g/dL) 0.008 Decrease  
BUN (mg/dL) 0.007 Increase 
Pump Flow 0.007 Increase when axial flow 
Creatinine (mg/dL) 0.006 Increase 
LDH (u/L) 0.006 Decrease when LDH increases 
ECG Rhythm 0.006 Increase with Atrial Fibrillation 
Frailty (INTERMACS 
definition)21 
  
0.005 Increase  
Peripheral Vascular Disease 0.005 Increase 
Time Since Cardiac Diagnosis 0.005 Increase with time since diagnosis 
ALT (U/L) 0.005 Decrease when ALT increases 
Allopurinol 0.005 Increase when used 
Working  0.005 Increases if patient not working 
Chronic Renal Disease 0.004 Increase 
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Post-implant Risk of Recurrent GI Bleeding Model and Results 
Variables used in the post-implant risk of recurrent GI bleeding event model included 
independent patient variables (e.g., patient age), medications at the time of the initial GI bleeding 
event and lab values and adverse events experienced by the patient within one week of the initial 
GI bleed. Out of 92 variables that went into feature selection, 16 were selected for the post-
implant TAN risk model (Figure 12). Final cross-fold validation ROC AUC was 61% (Figure 
13). More recent data from INTERMACS (n=1,236 patients), which was not used in the model 
learning, was used to validate model performance. In this test set, 39% of patients experienced a 
recurrent GI bleeding event. The test validation had a performance of ROC AUC of 60% (Figure 
13). 
 
 
Figure 12. Tree Augmented Naive Bayesian network of post-implant recurrent GI bleeding event risk. 
Arrows indicate a relationship between variables, with arrow thickness indicating strength of relationship. 
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Figure 13. Receiver operating characteristic curve for post-implant risk of recurrent GI bleeding events, 
cross fold and test validation 
 
Of the 16 model variables, the most predictive were: hematocrit and hemoglobin, age, 
and plasma free hemoglobin (Table 8). Four of the 16 variables were treatments, possibly 
modifiable by clinicians. The rest were lab values from the time of the initial bleed (6), 
independent variables (4), and time and location of the bleed (2). 
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Table 8. Variable in post-implant reoccurrence model and impact on risk 
Variable Diagnostic 
Value 
Increase or Decrease 
Risk 
Category 
Hematocrit (Max) 0.042 Decreases Lab 
Hemoglobin (Max) 0.014 Decreases Lab 
Age 0.014 Increases Pre-implant, Independent 
Min Hemoglobin 0.011 Decreases Lab 
Plasma-free 
Hemoglobin 
0.01 Increases Lab 
Interval to initial 
bleeding event 
0.008 Decreases with time Independent 
White Blood Cell 
Count 
0.007 Decreases Lab 
Hemoglobin (Min) 0.007 Decreases Lab 
Hemoglobin at bleed 
event 
0.007 Decreases Lab 
Heparin 0.007 Decreases Treatment 
Inotrope Therapy 0.005 Decreases Treatment 
Aspirin 0.004 Decreases Treatment 
Antiplatelet Count 0.004 Decreases Treatment, summary 
Pump flow: 
Centrifugal 
0.004 Decreases Pre-implant, Independent 
Location: Upper GI  0.003 Increases Independent 
LVAD or BiVAD 0.003 BiVAD decreases Pre-implant, Independent 
2.2.4 Discussion 
We present the first risk models for recurrent GI bleeding in patients with CF-LVADs, 
using Bayesian networks to analyze both pre- and post-implant risk factors. The pre-implant 
predisposition model performed with a ROC AUC of 0.68, while the post-implant risk model 
was less successful with a ROC AUC of 0.60. Both models identified features of high risk 
patients and provide insight into the complex pathophysiology of GI bleeding associated with 
CF-LVAD use. 
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The greatest predictor of pre-implant predisposition for recurrent GI bleeding events was 
patient age. This is in line with findings from previous studies of GI bleeding risk factors[57, 63-
65]. Old age is also a predictor of spontaneous AVM formation in elderly patients without heart 
failure[66].  
In addition to age as an objective measure, INTERMACS captures the subjective 
physician assessment of a patient being of “advanced age”, which is independent from actual 
patient age. Initially used to indicate whether a patients’ age prevents them from receiving a 
heart transplant, the definition was expanded to include any concern about implanting an LVAD 
that a physician may have due to the patient’s age[67], such as frailty. This indicator is an 
important factor in the pre-implant predisposition model; for example, patients who are 
considered “advanced age” in the 60-69 years old group have higher risk of recurrent GI 
bleeding (20% risk) compared to patients 60-69 years of age who are not “advanced age” (14% 
risk) or patients who are “advanced age” and 70-79 or 80+ years (18% risk for both). The 
inclusion of physician intuition increases the utility and performance of the predisposition model.  
A similar factor indicating patient overall health is patient work status. Patients who work 
either full or part time at the time of the CF-LVAD implant have a lower risk of recurrent GI 
bleeding. This is probably due to these patients being more likely to be younger and in better 
health than those who are not working. This relationship with working and better outcomes has 
also been seen in patients with heart transplants[68]. 
Patient age is a related factor with other variables in the predisposition model, such as 
device strategy (DT) and type of pump (HeartMate II). DT patients are typically older than BTT 
patients and the only device approved for DT at the time of this data collection was the 
HeartMate II, which is an axial flow device. This relationship between age and device strategy 
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has also been noted in the literature [57]. However, these additional variables do help 
differentiate risk in the predisposition model, for example: a 65-year-old patient who is BTT and 
listed for transplant has a 7% risk of recurrent GI bleeding if on a centrifugal flow pump, 
compared to a 12% risk for a similar patient on an axial flow pump. Similarly, the 65 years-old 
listed as DT on an axial flow pump has a 20% risk of recurrent GI bleeding. 
The type of pump flow has been associated with factors that may impact GI bleeding risk. 
Centrifugal flow pumps have less hemolysis [69], possibly due to their lower rotations per 
minute and/or lower blood-pump contact area. This lower hemolysis may decrease angiogenesis 
and therefore AVM-related GI bleeding [59]. However, other studies suggest that the pump 
design differences contribute less to the risk than the confounding age and device strategy factors 
[59, 60].  
Hemoglobin/hematocrit (Hgb/Hct) levels were influential factors in both the pre- and 
post-implant risk models for recurrent GI bleeding. Low pre-implant Hgb was associated with a 
higher risk of post-implant recurrent GI bleeding events. While pre-implant Hgb alone may not 
be a causal factor, the etiology behind the low Hgb is the likely factor driving recurrent GI 
bleeding risk, as it may indicate persistent, low grade GI bleeding [70].  
Similarly, low post-implant maximum Hgb/Hct, the highest Hgb/Hct levels between the 
patients’ last follow up and the time of the first GI bleeding event, were associated with an 
elevated risk of GI bleeding recurrence. Another potential explanation for the low maximum 
Hgb/Hct is subclinical hemolysis due to the CF-LVAD created shear stress and blood-metal 
interface [71]. This is further supported by high plasma-free hemoglobin as an additional risk 
factor. Hemolysis is a surrogate for turbulent flow beyond the design parameters of the device; 
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such turbulence facilitates degradation of vWF and is thought to further impair vWF-regulated 
angioneogenesis with increased risk of AVM formation [59].   
The post-implant model identified anticoagulants (aspirin, heparin) and inotropes as 
predicting a lower risk of recurrent GI bleed. Whether these treatments were maintained between 
the first and second GI bleed event and at what doses were not assessed, therefore few 
conclusions can be made as to their role in preventing recurrent GI bleeding. One explanation 
may be successful adjustment of anticoagulation regimens: if anticoagulation contributes to a 
first GI bleeding event, it can be adjusted to prevent a recurrence of bleeding. Inotrope use may 
be connected to the pulsatility-related mechanism of GI bleeding; single center evidence has 
shown that inotropes, specifically epinephrine, can increase cardiac pulsatility and decrease GI 
bleeding risk [72]. However, the association of inotrope therapy with decreased recurrent GI 
bleeding in our model may be confounded by very sick patients on inotropes dying before they 
have a recurrent GI bleed. Similarly, patients on BiVADs have lower risk of recurrent GI bleeds, 
likely due to their diminished overall survival[73]. 
These models can be used to identify patients at risk for recurrent GI bleeding and allow 
for more careful planning for and management after CF-LVAD implant. For example, patients 
with low pre-implant Hgb may benefit from capsule endoscopy assessment prior to implant 
surgery to rule out pre-existing sources of GI bleed.  
The pre-implant predisposition for GI bleeding model adds to the tool kit of risk 
assessments that physicians can use when making decisions about the care and management of 
patients receiving LVADs [27, 39, 74, 75]. The post-implant risk model highlights the potential 
CF-LVAD related causes of GI bleeding. While the present ROC AUC is modest, this is an 
important step to improving prediction and understanding of GI bleeding in CF-LVAD patients. 
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These predictive models will be made available to clinicians to evaluate as part of the Cardiac 
Outcomes Risk Assessment (CORA) decision support tool, which is available for demonstration 
use at www.app.mycora.org.  
Limitations: 
The data collected in INTERMACS for GI bleed does not separate AVM related bleed 
from other sources of GI bleed. This is a major hindrance in being able to classify the etiology of 
GI bleeding, particularly with how it relates to the CF-LVAD implant. Future work will use data 
from individual clinical sites that specifies AVM etiology to hypothesize physiologic reasons for 
the elevated AVM bleed risk. Another limitation is the low ROC AUC for the post-implant 
recurrent GI bleeding risk model. This may be due to the open-ended time interval used for 
recurrent GI bleeding. New models that examine recurrent GI bleeding over specific intervals 
(e.g., within 3, 6, or 12 months) could exclude patients who passed away or were transplanted 
and may improve predictive performance. 
2.2.5 Conclusions 
The important risk factors for recurrent GI bleeding can be identified for patients before 
they receive an LVAD implant and after an initial bleed occurs. The primary predictors for 
bleeding in both models are patient age and hemoglobin levels. Subclinical bleeding and possible 
hemolysis from CF-LVAD function may increase risk of GI bleeding in CF-LVAD patients. 
Physicians can use these models to identify high risk patients to monitor them for bleeding, as 
well as consider the best pump type to implant. Further work is required to identify the origin of 
the GI bleed, be it AVM or other causes, and determine the influence of specific risk factors on 
the pathophysiologic mechanisms driving GI bleeding.     
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2.3 RISK FACTORS FOR ISCHEMIC STROKE AFTER CF-LVAD IMPLANT BY 
PUMP TYPE 
Abstract: The risk of stroke continues to be a major adverse event after CF-LVAD 
implantation, limiting the utility of CF-LVADs. Ischemic stroke risk is directly related to factors 
arising from the pump-person interaction of the CF-LVAD, but these factors may differ by pump 
design. Using a Bayesian Network machine-learning approach, we predicted pre-implant risk for 
ischemic stroke in patients with axial or centrifugal flow pumps at 3 months after LVAD 
implant. Features of high risk patients on axial flow pumps were elevated c-reactive protein, 
invasive interventions during the CF-LVAD hospitalization and myocardial infarction. The 
features of high risk patients on centrifugal flow pumps were smaller patients, not using diuretics 
or antihypertensive medications. Common factors to both pump types were old age and elevated 
blood pressure. The performance of the risk predicting Bayesian model was a ROC AUC of 61% 
for axial and 66% for centrifugal flow pumps. 
2.3.1 Introduction 
Stroke is one of the most devastating adverse events affecting patients who receive a 
continuous flow left ventricular assist device implant (CF-LVAD). It is associated with high 
mortality and morbidity [76, 77], reduced patient quality of life, and impaired candidacy for 
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heart transplant [78]. Due to the high level of adverse effects, the risk of stroke is one of the main 
reasons CF-LVADs are not recommended for use in the less-sick heart failure patient population 
[79]. 
Strokes occurring in CF- LVAD patients can have either a hemorrhagic or ischemic 
etiology, with incidence of each type reported from 0-16% and 4-17.1%, respectively [80]. The 
causes of and treatment for each stroke pathology are different [81]; therefore the factors 
impacting post-CF-LVAD risk may also be different. For this reason, the present study focuses 
solely on causes and risk factors for ischemic stroke. 
Ischemic stroke falls into the category of CF-LVAD adverse events that arise from the 
pump-patient interface [82]. The interaction of blood with the metal interface, potential blood 
damage from the high-speed rotors, change to continuous blood flow, and increased potential for 
infection are all pathology-effecting factors that arise from the use of the CF-LVAD. Because of 
this, it makes sense that the device type, surgical technique and associated medical management 
may impact the risk of resulting adverse events, like stroke. In fact, recent data has indicated that 
pump type does play a role in stroke incidence and risk mitigation [83, 84]. However, analysis of 
the pre-operative predictive risk factors for ischemic stroke do not often distinguish between the 
two main pump types being used clinically [76, 84]. 
The goal of this study is to identify and compare pre-operative patient features associated 
with an elevated risk of ischemic stroke after axial or centrifugal CF-LVAD implant. Differences 
between the risk factors associated with each pump type can help identify the causative factors 
for ischemic stroke and be used in decision making for selecting appropriate CF-LVAD 
candidates.   
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Bayesian models were used to create the risk predictions in this analysis due to their 
ability to handle the interaction of many related pre-operative variables.   
2.3.2 Methods 
Data set and definitions 
The data for this study was derived from the Interagency Registry for Mechanical 
Assisted Circulatory Support (INTERMACS), funded by the National Heart, Lung and Blood 
Institute, National Institutes of Health, Department of Health and Human Services under 
Contract No. HHSN268201100025C. More information is available at: www.intermacs.org. IRB 
approval was obtained through the hospitals participating within INTERMACS. 
Ischemic stroke was defined as a neurologic adverse event that was an 
ischemic/embolism type of cerebrovascular accident (CVA), using INTERMACS nomenclature.  
 
Patient cohort 
Inclusion criteria for this study were the use of a CF-LVAD as the primary implant and 
age over 18 years old. Patients who received Bi-VAD (left and right VADs) were included. Total 
artificial heart implants and pulsatile LVAD implants were excluded. The time frame for 
implants was between 2012 and 2016. Patients were censored for transplant, explant, or non-
ischemic stroke related death before 3 months post-CF-LVAD implant.  
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Data pre-processing 
Pre-implant patient data was split into two patient populations: patients receiving a 
primary axial flow pump and patients receiving a primarily centrifugal flow pump. Outcomes for 
each data set were occurrence of an ischemic stroke within 3 months of CF-LVAD implant.  
Data was processed by discretizing continuous variables using equal width binning for 
each of the two patient populations. This method was determined by comparing the information 
gain of each variable after discretization by three different methods: supervised binning, equal 
width binning, or equal frequency binning and selecting the method that had the highest 
information gain. This was done independently for the axial flow and centrifugal flow models. 
The number of bins was determined by comparing the Naïve Bayes model performance with 
continuous variables split into 2 to 10 bins and selecting the version with the highest receiver 
operating characteristic area under the curve (ROC AUC). In the axial flow model, continuous 
variables were discretized into 10 equal width bins, and, in the centrifugal flow model, 
continuous variables were discretized using 7 equal width bins. 
 No imputation was performed for missing data.  
 
Variable feature selection and model training 
Data for each time point was divided into two parts: a training data set comprising 80% 
of the data, and a test set of 20%. Splits were made randomly in Weka. Training data was used 
for feature selection and model structure and parameter learning, while test data was only used in 
the final performance validation.  
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Feature selection was performed using information gain and hill climbing (Weka) to 
select the variables most related to ischemic stroke risk for each pump type. Information gain 
threshold was set at gain > 0.003. 
Using the resulting feature selected variables, a Tree Augmented Naïve Bayes (TAN) 
model and a Naïve Bayes (NB) model were created (GeNie, BayesFusion, Pittsburgh, PA) to 
classify the outcomes for each pump type. The initial models were validated by 10-fold cross 
validation and each variable was evaluated for diagnostic value. Diagnostic value is a measure of 
the influence the variable has on the model prediction, based on the expected gain in cross-
entropy. The lowest ranked variables were removed, and the model was re-learned and then 
validated with 10-fold cross validation. Variables were iteratively removed and added until the 
model performance, defined by ROC AUC, no longer improved. This procedure was performed 
independently for the axial and centrifugal flow patient populations. Outcomes from the TAN 
and NB models were compared to select the best performing model. 
 
Model validation 
The test set of data, comprising 20% of the initial patient data set, was used for 
performance validation of the final axial and centrifugal flow ischemic stroke models. The test 
data sets were also used to measure the performance of a recently published ischemic risk score 
[76]. 
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2.3.3 Results 
Patient cohort 
Out of 13,593 patients who received CF-LVADs between 2012 and 2016, 937 (7%) 
patients experienced an ischemic stroke at some point after implant. Of these ischemic strokes, 
32% were fatal. Of the patients who experienced ischemic stroke, 47% had them by 3 months 
after implant (Figure 14). When considering timing by pump type, 45% of axial pump and 57% 
of centrifugal pump ischemic strokes occurred by 3 months after implant. 
 
 
 
 
 
 
Figure 14. Time to ischemic stroke, by pump type. Percent shown is of total patients who 
had an ischemic stroke, by pump group. 
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The average patient centrifugal flow patient with an ischemic stroke was younger (56 vs 
60 years of age, p-value < 0.0001), bridge to transplant (92% vs 35%, p-value < 0.0001) and 
more likely to be INTERMACS profile 2 (38% vs 27%, p-value = 0.0040). All other descriptive 
factors had no statistically significant differences between pump groups (Table 9).  
 
Table 9. Comparison of Patient Features by Adverse event of Ischemic Stroke 
  Patients with Ischemic Stroke after CF-
LVAD  
 
Characteristic  Axial Flow, 
n = 685 
Centrifugal Flow, 
n=252 
p-value 
Age Mean (StdDev) 60 (11) 56 (10) < 0.0001 
Gender Male 175 100% 58 100% 0.4715 
Race White 490 71% 163 64% 0.2543 
 African 
American 
145 21% 57 23% 0.6643 
 Other 51 7% 33 13% 0.0084 
Device Strategy BTT 241 35% 233 92% < 0.001 
 DT 435 64% 19 8% < 0.001 
 Other 9 1% 0 0% 0.0688 
Blood Type O 306 45% 119 47% 0.5518 
 A 265 39% 82 33% 0.1313 
 B 85 12% 35 14% 0.5592 
 AB 22 3% 14 6% 0.0994 
NYHA II 1 0% 1 0% 0.4605 
 III 109 16% 46 18% 0.4105 
 IV 534 78% 193 77% 0.7833 
INTERMACS 
Profile 
1 122 18% 41 16% 0.5996 
 2 187 27% 95 38% 0.0040 
 3 249 36% 82 33% 0.3381 
 4 106 15% 24 10% 0.0260 
 5 13 2% 7 3% 0.4099 
 6 6 1% 1 0% 0.4515 
 7 2 0% 2 1% 0.2965 
 
Data is shown as the total in each category and percentage of total, with comparison 
between axial and centrifugal flow pump patient groups using two-way z-test. DT, Destination 
Therapy; BTT, Bridge to Transplant (includes patients listed and not-yet listed).  
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Axial flow model 
Between 2012 and 2016, 9,159 patients received axial pump CF-LVADs, 307 (3.4%) of 
whom had ischemic stroke within 3 months after implant. The axial pump model structure and 
parameters were constructed using a training set of 7,327 patients, 243 of whom (3.3%) had 
ischemic stroke within 3 months. 
Of the 247 pre-implant variables that went into feature selection, 53 were identified as 
potential predictors using information gain and hill climbing methods. These were used to build 
both TAN and NB models in GeNie. Variables were assessed for diagnostic value, low value 
variables were removed, and a new model was learned. This was done iteratively until 
performance, measured by ROC AUC from 10-fold cross validation, was optimized. The best 
performing axial pump model was with NB and included 32 variables (Figure 15).  Model 
performance was measured with a test validation dataset (n=1832). For this axial flow patient 
population, 3.5% of patients (64 of 1832) had an ischemic stroke by 3 months. The model had a 
ROC AUC of 0.61 (Figure 16). 
 56 
 
Figure 15. Tree augmented naive Bayesian network of ischemic stroke risk at 3 months with an axial flow 
pump 
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Figure 16. Receiver operating characteristic curve for model of ischemic stroke risk at 3 months with an 
axial flow pump 
 
Centrifugal flow model 
There were 2,909 patients implanted with a centrifugal flow pump between 2012 and 
2016, 137 (4.7%) of whom had ischemic stroke within 3 months of implant. 
Model structure and parameter learning was performed with a training data set of 2,377 
centrifugal flow pump patients, 115 (4.9%) of whom had an ischemic stroke by 3 months. 
Out of the 246 pre-implant variables that were used in feature selection, 50 were 
identified as top predictors using information gain and hill climbing. As with the axial flow 
pump model, the selected variables were used to build both TAN and NB models in GeNie. 
Variables were assessed for diagnostic value, low value variables were removed, and 
performance was measured with 10-fold cross validation until ROC AUC was optimized. The 
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best performing model was achieved using TAN and included 36 variables (Figure 17). Model 
performance was measured with a test validation dataset (n=582). In this dataset, 3.8% of 
patients with a centrifugal flow pump (22 of 582) had an ischemic stroke by 3 months. The 
model had a ROC AUC of 0.64 (Figure 18). 
 
 
Figure 17. Tree augmented naive Bayesian network of ischemic stroke risk at 3 months with a centrifugal 
flow pump 
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Figure 18. Receiver operating characteristic curve for model of ischemic stroke risk at 3 months with a 
centrifugal flow pump 
 
Comparison of Axial and Centrifugal Flow Model Variables 
Key variables in each of the predictive models are captured in Table 10. 
Top predictors for the axial pump ischemic stroke model were: elevated C-reactive 
protein levels, elevated uric acid, previous use of temporary circulatory support, small left 
ventricular end diastolic diameter, and being too sick to take the Kansas City Cardiomyopathy 
Questionnaire (KCCQ). Both admission due to myocardial infarction (MI) and major MI were 
predictive of higher stroke risk. Demographic features affecting stroke risk were old age, female 
sex, and African American race.  
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The most predictive variables for the centrifugal pump model were: elevated uric acid, 
destination therapy (DT), hospital implant volume over 50 per year, no use of loop diuretics, and 
short height. Unique to this model is the risk factor of giant cell myocarditis, presence of ascites, 
and unfavorable mediastinal anastomosis. The only demographic factor affecting stroke risk of 
patients with centrifugal flow pumps was old age. 
Out of the 67 features in the two models, 13 are in both models and 41 are unique. The 
main differences between the two are more medication variables in the centrifugal flow model 
(norepinephrine, loop diuretics, warfarin, aldosterone, dobutamine, and amiodarone). In the axial 
flow model, there are more events during hospitalization risk factors (dialysis, intubation, 
feeding tube, ultrafiltration, and major MI). 
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Table 10. Variables by diagnostic value in the axial and centrifugal pump patient populations 
Axial Flow Centrifugal Flow 
Variable 
Diagnostic 
Value Variable 
Diagnostic 
Value 
C-reactive protein 0.019 Uric acid 0.025 
Uric acid 0.015 Device strategy (DT) 0.023 
Temporary circulatory support 0.014 Hospital implant volume 0.017 
LVEDD 0.014 Loop diuretics 0.015 
Reason for not taking KCCQ 0.013 Height 0.014 
Pre-Albumin 0.012 IV Norepinephrine 0.013 
On ventilation during hospitalization 0.011 LVEDD 0.013 
Admission due to MI 0.01 Giant cell myocarditis 0.012 
Intubation during hospitalization 0.01 Previous cardiac operations? 0.012 
Major MI during hospitalization 0.009 On ventilation during hospitalization 0.012 
Platelet count 0.009 ECMO during hospitalization 0.012 
Ischemic etiology 0.008 History of MCS 0.011 
Previous cardiac operations? 0.008 Previous ECMO 0.01 
Previous CABG 0.008 Weight 0.01 
On ECMO 0.008 Potassium 0.01 
Sodium 0.008 Pulmonary arterial systolic pressure 0.01 
Pulmonary arterial diastolic pressure 0.008 Pulmonary arterial diastolic pressure 0.01 
INTERMACS profile 0.007 Age  0.009 
Albumin 0.007 Pulmonary wedge pressure 0.009 
Diastolic blood pressure 0.007 Frailty 0.008 
Hospital implant volume 0.006 Ascites 0.008 
Dialysis during hospitalization 0.006 
Non-cardiac surgery during 
hospitalization 0.007 
Events during hospitalization? 0.006 LDH 0.007 
Ultrafiltration during hospitalization 0.006 Unfavorable mediastinal anastomosis 0.006 
Feeding tube during hospitalization 0.006 Admission due to MI 0.006 
History of MCS 0.006 Cardiac surgery during hospitalization 0.006 
Mitral regurgitation 0.006 Right ventricular ejection fraction 0.006 
Height 0.006 Heart rate 0.006 
Systolic blood pressure 0.006 Warfarin 0.005 
Hemoglobin 0.005 Platelet count 0.005 
Age 0.004 Current ICD 0.004 
African American 0.004 Aldosterone 0.004 
  
Diastolic blood pressure 0.004 
  
IV Dobutamine 0.003 
  
Amiodarone 0.003 
LVEDD, Left Ventricular End Diastolic Diameter; KCCQ, Kansas City Cardiomyopathy questionnaire; 
MI, Myocardial infarctions; CABG, Coronary arterial bypass graft; ECMO, Extracorporeal membrane oxygenation; 
MCS; Mechanical circulatory support; DT; Destination therapy; IV, intravenous; LDH, Lactate dehydrogenase; 
ICD, implantable cardioverter defibrillator. 
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Comparison of models to contemporary risk score  
To compare the models’ performance to a published risk score, we evaluated the same 
test data sets with the INTERMACS stroke score [76]. For the both the axial flow and centrifugal 
flow pumps, the risk score is not significantly associated with the rate of ischemic stroke (Figure 
19). Evaluating the risk score by ROC, centrifugal ROC AUC is 54.8% and axial is 58.8% 
(Figure 20). 
 
 
Figure 19. INTERMACs ischemic stroke risk score patient stroke incidence discrimination 
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Figure 20. Receiver operating characteristic curves for axial and centrifugal flow pumps using the 
INTERMACS ischemic stroke risk score 
2.3.4 Discussion 
Patient factors affecting risk of ischemic stroke can be identified before CF-LVAD 
implant, and the factors driving ischemic stroke risk type differ by type of device being 
implanted.   
The two device types being compared in this study were axial and centrifugal flow 
pumps. At the time of this data collection, only axial flow pumps had been approved for 
destination therapy (DT). Patients who are DT are usually older or have co-morbid conditions, 
therefore it was not surprising that the axial flow patients were significantly older than the 
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centrifugal pump patients. Age is associated with increased ischemic stroke risk in both the 
predictive models generated in this study and in the literature for both VAD and non-VAD 
populations [85]. 
Despite patients being a higher age over all, axial flow pumps had a lower overall risk of 
ischemic stroke by 3 months compared to centrifugal flow pumps. This difference has been 
noted in other studies, where there were more events per patient year of ischemic stroke in 
HVAD (the only centrifugal pump approved at the time of this study) than in HeartMate II 
pumps (the only axial flow pump approved at the time of this study) [85]. This difference in 
incidence was not seen with hemorrhagic stroke. 
Pre-implant blood pressure has been identified as a modifiable factor that can affect risk 
of ischemic stroke [86], and can be successfully managed with hypertensives [87]. In the most 
recent INTERMACS report, a systolic blood pressure over 120mmHg was one of the key 
components of the predictive ischemic risk score [76]. Blood pressure is included in the axial 
flow predictive model in the form of systolic blood pressure, diastolic blood pressure, and 
pulmonary arterial diastolic pressure (PADP). Interestingly, of the three measures, PADP had the 
largest impact on risk prediction. In the centrifugal pump patient model, the blood pressure 
measures that drive risk are: Pulmonary arterial systolic pressure (PASP), PADP, pulmonary 
wedge pressure, and diastolic blood pressure. 
 
 
 
Admission to hospital due to myocardial infarction (MI) was a driver of ischemic stroke 
risk in both pump models, with major MI during hospitalization also being a factor for risk in the 
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axial pump model. MI causing an anterior infarction has been associated with increased risk of 
developing ventricular thrombi, which may dislodge to cause stroke [88]. Additionally, the 
hemodynamic change and inflammatory response to infarction may factor into subsequent stroke 
risk [89, 90].  
Uric acid has been widely studied as a risk factor associated with acute stroke in the non-
LVAD population [91-93], though whether it is an independent risk factor or a marker of 
atherosclerotic disease is not fully understood [94]. It is a predictive factor in both the axial and 
centrifugal pump models. Uric acid is also connected to platelet count and LDH in the 
centrifugal pump TAN model, suggesting that it is an indicator of associated disease and not just 
a factor on its own. 
Elevated C-reactive protein (CRP) was the primarily predictor for ischemic stroke in 
patients with an axial flow pump. CRP is a marker of inflammation and has been shown to be a 
strong predictor of ischemic stroke, MI, and death [95].  
In both pump models, interventions during the hospitalization before CF-LVAD implant 
drive the risk of ischemic stroke. This includes dialysis, intubation, feeding tube, ultrafiltration, 
and major MI in the axial pump model, ventilation and ECMO in both models, and cardiac or 
non-cardiac surgery in the centrifugal pump model. All the interventions are invasive and carry 
the risk of tissue inflammation and infection, as well as indicating an overall poorer health at the 
time of hospitalization for the patient.  
Use of loop diuretics and aldosterone are associated with lower ischemic stroke risk in 
patients with centrifugal flow pumps. This is in line with the connection between hypertension 
and stroke risk, were patients not being managed with these are at greater risk of becoming 
hypertensive after CF-LVAD implant. Use of amiodarone and IV dobutamine were also 
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associated with lower ischemic stroke risk. Atrial fibrillation has been highly associated with 
ischemic stroke risk [81, 96], though was not a selected feature in either risk model. The use of 
an anti-arrhythmic such as amiodarone may decrease stroke risk by minimizing occurrence of 
arrhythmias in these patients. IV norepinephrine was associated with increased ischemic stroke 
risk, potentially due to its vasopressor effect.  
Device strategy is a significant predictor for outcomes in the centrifugal flow pump 
model, with DT being the strategy associated with higher risk. Centrifugal flow pumps were not 
approved for DT at the time of this study, so the 2% of patients with them that were DT were 
technically off label. This rare off-label use is associated with ischemic stroke risk, however that 
may be due to other factors that caused the patients to be on off-label in the first place, such as 
very small body size and older age (the DT-approved axial flow pump is larger and may not be 
tolerated as well in very small patients.) Patient size by height and weight was also a predictor of 
centrifugal pump ischemic stroke, with smaller patients having higher risk.  
Gender was not a predictor in either model, despite it being commonly reported as a risk 
factor in other literature [76, 97]. In one study, the relationship between the higher risk of 
females having ischemic stroke was characterized in context of their smaller size, which was a 
predictive factor in our centrifugal pump model, and their risk of thromboembolism due to the 
use of oral contraceptives or hormones [98].  
 
 
Comparing the predictive strength of our resulting models to the current published risk 
score, we demonstrated superior performance. The current predictive performance of our models 
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at 61% and 64% ROC AUC for the axial flow and centrifugal pump models, respectively, shows 
moderate predictive power. 
This study was limited by the large amount of missing data, particularly for lab values, 
which ranged from (5-72% missing). Data is manually entered into INTERMACS and may be 
subject to errors in entry. However, this study is the largest of its kind to compare outcomes by 
pump type and the first to derive independent predictive models for ischemic stroke. Future work 
will explore additional time points, including early (within 2 weeks of implant) stroke and late 
stroke 12 months, as well as risk factors for hemorrhagic stroke, the less common but deadlier of 
the stroke types in LVAD patients. 
2.3.5 Conclusion 
By using a Bayesian approach, we explored pre-implant factors that are predictive for 
ischemic stroke and their relation to the type of pump. Patients on centrifugal flow pumps have a 
higher ischemic stroke risk, but selection of the right patients can mitigate this increased risk. 
Factors driving overall risk include blood pressure, which can be pre-operatively managed, and 
incidences of invasive interventions. These models may be utilized to identify optimal candidates 
for LVAD implantation that have a lower risk of ischemic stroke. 
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3.0 AIM 2: VERIFICATION OF MORTALITY MODELS AND PHYSICIAN USE CASE 
FOR LVAD DECISION SUPPORT 
3.1 RETROSPECTIVE EVALUATION OF MORTALITY MODELS AT SINGLE 
IMPLANT CENTER USING COMPLETE PATIENT DATASET 
3.1.1 Introduction 
Heart failure is a chronic, progressive condition that affects over 6 million Americans. It 
is characterized by a decline in function of the heart to pump enough blood to perfuse the body 
[1]. As the condition progresses, treatments may escalate from dietary modification and oral 
medications to intravenous drug delivery and surgical interventions, such and mechanical heart-
assist pumps and heart transplantation [2]. Heart transplant is the gold standard treatment for end 
stage heart failure; however, donor heart supply is limited and not all patients are eligible for 
transplant, due to their age, comorbid conditions, or lifestyle choices. As an alternative, advanced 
heart failure patients may receive a durable left ventricular assist device (LVAD) as a bridge to 
transplant (BTT) or as a destination therapy (DT) [10].  
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LVADs can increase quality of life and improve patient survival [7, 8], but also require 
significant changes in daily life, investment of time and money, and introduce risks of major 
adverse events [9]. These tradeoffs underscore the importance of careful patient selection, for 
which predictive models can serve as an important component of risk assessment. 
We recently published models to predict post-LVAD mortality at 1, 3, and 12 months 
after implant [75] using the data from the Interagency Registry for Mechanically Assisted 
Circulatory Support (INTERMACS), the largest registry of retrospective LVAD patient data in 
the United States [7]. The models were developed using Bayesian analysis and validated with a 
subset of registry data that was withheld from the model derivation. While use of the large 
registry dataset provides a robust model, it obscures institution-dependent differences in patient 
selection, care, and outcomes. Use of a personalized decision support tool in a ‘real world’ 
clinical setting is necessary to understand its applicability at individual institutions.   
The INTERMACS registry includes a large population (n = 20,216) of LVAD patients 
but suffers from missing data and entry errors. Because data is entered manually by LVAD 
coordinators and nurses at each participating site, there are inevitable errors such as misplaced 
decimal points, incorrect units, and skipped fields. No data checks are imposed on the data entry 
process, therefore any information that is unusual or out of range is not flagged. When we 
developed the Bayesian models with these data, out-of-range or illogical data entries were 
censored; however, missing data was left as-is, instead of being imputed, to minimize over-
fitting. The extent to which these issues affect the performance of the Bayesian predictive 
models is unknown; therefore, a carefully checked and evaluated dataset from a single clinical 
site was used to measure model performance. 
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This study was undertaken to establish the performance of our Bayesian models for 
LVAD mortality at a single institution with a complete, retrospective patient data set. The goal of 
this work was to prove the utility of the models for use in prospective patient risk assessment. 
3.1.2 Methods 
Data acquisition and cleaning 
We acquired site-specific INTERMACS data for 100 consecutive patients who received a 
CF-LVAD at Allegheny General Hospital (AGH) between 2014 and 2015. A data sharing 
agreement was established between Carnegie Mellon University (CMU) and AGH to assure the 
security of protected health information in this study. This study was approved by CMU and 
AGH’s review boards for biomedical research (IRBs). 
The time-period was selected to include records with at least 1 year of follow up data. 
The data was organized into three categories: Pre-Implant, Post-Implant, and Event. Missing or 
illogical data (outside of feasible range or conflicting with other entries) was manually identified 
and checked by a data coordinator. Data elements that were designated as “unknown” or 
“missing” were addressed by reviewing all available patient medical records. In cases where the 
data could not be found, the data field was denoted as “not recorded.” All units for continuous 
variables were also checked. Once all 100 patients were verified by the coordinator at AGH, the 
data set was sent to CMU for analysis.  
Data pre-processing 
Pre-implant continuous data were binned into groups as previously described [75]. 
Mortality outcomes were assigned to each patient using the Event data for each of the three time 
points: 1, 3, and 12 months post LVAD. 
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Model validation 
The complete AGH data sets were used to measure the Bayesian mortality model 
performance for each time point, using test validation in GeNie (BayesFusion, Pittsburgh, PA). 
3.1.3 Results 
Data cleaning revealed 9% of all pre-implant information (2704 out of 28500 possible 
fields) was missing or out of range in the patient records. After data cleaning, this was reduced to 
4% (1184) fields that were confirmed as not recorded. 
The patient cohort at AGH was similar to the overall INTERMACs population in terms 
of patient age and gender (Table 11.) The main statistical differences between cohorts were the 
proportion of INTERMACS profile 2 and 3 patients. This difference indicates a sicker patient 
population in the AGH cohort than the INTERMACS patients overall.  
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Table 11. Patient cohort comparison 
  
AGH Patients  
(n=100) 
INTERMACS Patients (n 
= 10,277)  
Characteristic 
 
n % n % p-value 
Age Mean (std) 56.2 (12.7) 56.9 (13) 0.59197 
Gender Female 27 27% 2225 22% 0.19706 
 
Male 73 73% 8044 78% 0.20408 
NYHA I 0 0% 12 0% 0.72786 
 
II 2 2% 88 1% 0.2187 
 
III 55 55% 1850 18% < .001 
 
IV 26 26% 7816 76% < .001 
 
Unknown/ Not 
documented 17 17% 511 5% < .001 
INTERMACS 1 20 20% 1671 16% 0.3125 
 
2 48 48% 3548 35% 0.0048 
 
3 14 14% 3318 32% 0.0001 
 
4 15 15% 1340 13% 0.56192 
 
5 0 0% 230 2% 0.13104 
 
6 2 2% 58 1% 0.0601 
 
7 1 1% 41 0% 0.34722 
 
Unknown 
 
0% 71 1% 0.40654 
Ischemic Etiology No 48 48% 5640 55% 0.16758 
 
Yes 52 52% 4637 45% 0.16758 
Device Strategy BTT Likely 67 67% 5261 51% 0.00164 
 
BTT Unlikely 5 5% 267 3% 0.13362 
 
DT 25 25% 4658 45% < .001 
 
Other 3 3% 91 1% 0.02642 
NYHA, New York Heart Association class; INTERMACS, Interagency Registry for Mechanically Assisted 
Circulatory Support; BTT, Bridge to transplant; DT, destination therapy. 
 
One month after implant, 4 (4%) of the 100 AGH patients had died. Then NB mortality 
model correctly predicted 3 out of the 4 deaths (75%) and predicted 87 out of 96 alive patients 
(91%), using a threshold of 50%. The ROC AUC was 78%. This is better performance than the 
original model validation of 70% ROC AUC (Figure 21).  
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Figure 21. ROC curves for 1-month mortality from original and AGH-specific validation 
 
At three months after implant, 8 (8%) of the 100 patients had died. The NB mortality 
model correctly predicted 4 of the 8 deaths (50%) and 83 of the 92 living patients (90%), using a 
determination threshold of 50%. The ROC AUC for the model performance was 76%. This is 
superior to the original model test validation of 71% (Figure 22). 
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Figure 22. ROC curves for 3-month mortality from original and AGH-specific validation 
 
By twelve months after implant, 18 (18%) of the 100 patients had died. The NB mortality 
model correctly predicted 6 of the 18 deaths (33%) and 73 of the 82 living patients (89%), using 
a determination threshold of 50%. The ROC AUC for the model performance was 75%, which 
was better that the original model validation of 69% (Figure 23). 
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Figure 23. ROC curves for 12-month mortality from original and AGH-specific validation 
 
3.1.4 Discussion 
We had previously reported ROC AUCs of 70%, 71%, and 69% for Bayesian mortality 
predictions at 1, 3 and 12 months post-LVAD implant with a validation cohort from 
INTERMACS. All three mortality models performed better in the AGH patient dataset than in 
the INTERMACS validation cohort. The AGH patients had similar demographics to the patients 
in the model learning dataset, however there were significantly more patients with severe heart 
failure, as indicated by the percentage of patients with INTERMACS 2 classification. 
One of the explanations for the better performance with AGH patient data is the greater 
proportions of severe heart failure patients. Recent analysis by our group has demonstrated that 
the Bayesian mortality models perform better in the more severe heart failure populations 
(Kanwar et al, in preparation). The INTERMACS profile 1 patient group had ROC AUCs of 
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71% for each of the 1, 3, and 12-month time points and the profile 2 patient group had ROC 
AUCs of 74%, 75%, and 70% for the time points. These are the same or better performing than 
the validation with all patients. The difference in performance may be attributed to the greater 
proportion of data available for the sicker patients. Bayesian models are derived using prior 
probabilities and thus are more accurate when applied to patient populations that comprise a 
greater percentage of the derivation cohorts. Another reason for the difference may be that the 
factors that increase a patient’s risk of dying (such as recent cardiac surgery, advanced age, and 
dialysis) are easy to capture in the dataset, while it is much harder to identify and quantify 
features that predict a patient’s good health and survival.  
Before using the Bayesian mortality model predictions in clinical practice at an implant 
center, it is essential to verify their performance on that center’s specific patient population. This 
is especially important given the influence of institutional experience on outcomes. This is 
illustrated by the Heartmate II Risk Score, which includes institution implant volume as a 
statistically significant predictor for mortality outcomes[44]. Additionally, an assessment of 
implant center volume on one-year mortality of destination therapy (DT) patients found that low 
volume centers had a higher mortality rate [99]. Similar relationships have been reported for 
transplant graft survival[100] and right heart failure-associated mortality[101]. Since AGH is an 
experienced, high volume implant center, the models may perform better there than in a lower 
implant volume institution. 
The data cleaning step at AGH did not create a significant difference in missing data, 
with the majority (56%) of missing data elements identified as not recorded. The Bayesian 
method of modeling is robust to missing information when making predictions, and this is shown 
to be true by the resulting ROC AUCs. Whether having no missing data would improve the 
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model performance remains unknown. However, it is unlikely that any institution can have a 
value for every possible patient variable, making these models attractive for real world use.   
The models assessed in this analysis have been made available at app.myCORA.org, as 
part of the Cardiac Outcomes Risk Assessment (CORA) decision support tool for physicians 
(Figure 24.) This tool will now be prospectively evaluated with the multidisciplinary team at 
AGH to measure its impact on patient selection and decision making. Predictive models for post-
LVAD adverse events are being developed to add to the CORA tool (e.g., ischemic stroke, major 
bleeding) and will be evaluated for performance with the same single center, retrospective 
validation methodology. 
 
Figure 24. Screenshot of the app.myCORA.org web tool 
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3.1.5 Conclusion 
By validating the model set at a single clinical site, performance can be demonstrated for 
the patient population served at that site and for the unique surgical and medical management 
style of the clinicians. This exercise is imperative to confirm the utility of the mortality models 
for clinical decision making. Future work will be to prospectively test the model performance in 
the AGH multidisciplinary team meeting setting, to evaluate utility in real life decision making.  
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3.2 PILOT TESTING THE MYCORA PHYSICIAN USER INTERFACE  
If a tree falls in the woods, but no one is there to hear it, does it make a sound?  
If a decision support tool gives accurate predictions on patient outcomes, but no one 
takes the time to use it, does it help medical practice? 
3.2.1 Introduction 
Design of a clinical decision support tool must be carefully considered for the tool to be 
used in and improve upon medical practice. The government Medicare and Medicaid electronic 
health record (EHR) incentive program has clinical decision support (CDS) as one of its core 
focus areas [24]. This prompted a guidance document for a CDS framework. Called the “CDS 
Five Rights”, it states that CDS interventions should provide [102]:  
1. the right information (evidence-based guidance, response to clinical need)  
2. to the right people (entire care team – including the patient) 
3. through the right channels (e.g., EHR, mobile device, patient portal)  
4. in the right intervention formats (e.g., order sets, flow-sheets, dashboards, patient lists)  
5. at the right points in workflow (for decision making or action)  
In short, for a CDS to be effective, it must be relevant to those who use it to facilitate the 
right decision for the right patient at the right time. 
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While much research has been done in the field of LVAD decision making to address the 
first CDS tenet using the right information [26, 30, 44], the tenets of the right people, channel, 
format, and point in workflow have been largely neglected. This study addresses the issues of 
determining the right channel and intervention format for the myCORA decision support tool use 
by physicians. 
This pilot study tested the usability of the current myCORA decision support interface 
with physicians to inform the design of a large online study for quantitative measurement of 
usability, interpretation, and content quality. 
3.2.2 Methods 
Pilot testing was performed with one of the CORA clinical collaborators. The participant 
was asked to access the new myCORA interface on their own computer and to share their screen 
via Skype. The participant was asked to think aloud as they responded to questions about the 
interface and explain what they were doing and why. A preliminary script of questions was used 
to guide the participant through initial interface thought and two exercises, using patient 
information already in the myCORA tool and then entering information for a past patient. The 
screen of the user was video recorded with MouseFlow, a mouse tracking software, and audio 
recorded to augment note-taking. 
Responses were analyzed for themes in response in two main categories: layout and 
content. 
Mouse tracking heat maps were used to show the areas the users spent the most time one, 
where they had the most clicks, and where their attention was primarily focused.  
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3.2.3 Results 
Access 
Pilot user accessed the myCORA app through her personal laptop computer with the 
Safari internet browser. 
Initial Feedback 
Responses followed a natural flow from left to right. The most time was spent on reading 
and making sense of the content of the prognostic graphs, followed by scanning the variable 
input options. Themes covered in the initial feedback are summarized in Table 12.  
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Table 12. Responses to myCORA layout 
Layout Theme Example response 
Page layout “Icons on the left are easy to read, nice, understandable” 
Data presentation “Table is busy. Can see that it’s percentages but would like a better 
visual.”  
Model information • ‘Avg age 60’, interpreted as a healthy control patient 
• “Why are the x-axes different? This is misleading, because I 
naturally compare them to each other” 
Wording • “Wording confusing for ‘patient does not want transplant’–
should be ‘does patient want a transplant, yes/ no?’” 
• “What do ‘scenarios’ mean?” (in the model legend) 
Interaction • Variables are disappearing (moving from unobserved to 
observed) 
• Trying to change variable sorting to influence overall, used 
second drop-down option, which is dependent on the first 
 
First exercise (pre-entered data) 
When asked to interpret the prognosis graph information, respondent answered correctly 
and rapidly, using the information on the prognosis table at the top of the screen.  
When asked to name three un-observed variables for the demonstration patient, 
participant reported three titles of the variable groups, as opposed to individual variables, e.g., 
“laboratory values” instead of “creatinine”.  When asked to say what variable had the most 
influence on the survival outcome, participant knew to look for ranking of variables by their 
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influence, but originally selected the wrong dropdown box. After prompting by the interviewer, 
she successfully sorted by influence and reported the variable. At first, she paused to give the 
variable group title, but realized that the group titles had been removed when the sorting method 
changed.  
Second exercise (own patient data) 
When asked to create a new patient, participant knew to use the arrow at the back button 
to the main patient screen and found the “Add New” option quickly. Data for the initial patient 
information was entered without hesitation or question of why those items were chosen.  
Asked to enter patient information to determine outcome, the participant entered 13 
variables, only changing one during the process. She scrolled down the un-observed variable list, 
leaving in it “Group” mode. As each variable was selected it moved to the ‘observed’ list and 
effectively disappeared. This was met with frustration as some of the variables had dependents. 
Models were not seen to the left because she was answering variables down the page, out of view 
of the models. Thus, no change in model outcome was seen during data entry. 
Responding to model outcome, participant correctly interpreted the graph but was 
surprised at the survival prediction outcome. Participant did not seek to look at the variable 
influences until prompted. When looking at the most influential variable, concern about outcome 
was somewhat alleviated. Reponses about the content are summarized in Table 13. 
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Table 13. Response to myCORA model content 
Content Theme Example response 
Mortality prediction • “That is very poor prognosis, which is surprising because the 
parameters I entered are fairly common for our VAD patients” 
• “Why is SHFM included here? What is its purpose?” 
Other model predictions Did not view or comment on 
 
Post-exercise feedback 
When asked how this tool would be used in her practice, participant said she would most 
want to use it to evaluate ambulatory heart failure patients on medical therapy who need 
intermittent IV inotropes. Regarding when in the relationship with the patient (e.g., at time of 
diagnosis, during LVAD evaluation, immediately before surgery) this would be, she said it was 
different for every patient – a patient receiving a diagnosis in the ICU on ECMO wouldn’t be 
appropriate, but a patient earlier in their disease progression might be. 
In terms of usability, the participant indicated that though she was overwhelmed with the 
information at first (the summary table of prognoses, in particular) she felt more comfortable 
navigating the tool after some time using it. At one point when going to sort variables by 
influence the participant said, “I remember how to do this!” Prolonged use of the tool did not 
impact her perception of the model content, with concerns about the predicted patient prognosis 
being too dire persisting throughout the exercise.  
In closing, the participant said she liked how myCORA worked, but would not want to 
use it with patients until she better understood and believed the predictive models. It was 
suggested that model validation with her site’s contemporary data would help achieve this. 
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Mouse tracking analysis 
On the patient selection screen, mouse movement tracking revealed most attention spent 
looking through patient names and taking note of patient features, predominantly gender and 
NYHA level (Figure 25). The mouse action also shows tracing across a row of patient 
information. 
 
 
Figure 25. Heat map of mouse activity on patient selection screen 
 
Attention tracking, which is extrapolated from mouse clicks, movements, and scrolling, 
shows that the patient list is the area of main focus, with least focus on the navigation options at 
the bottom of the page (Figure 26). 
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Figure 26. Attention heat map of patient selection screen 
 
On the patient prognosis page during the user exercise, movement was concentrated 
around the survival model and observed variables (Figure 27). Because some of the observed 
variables had dependent dropdown options, movement was high over the additional fields to 
click on. Mouse activity decreased over the models, with no activity over the last three models. 
Attention was primarily on the survival model and decreases going down the screen 
(Figure 28). There are 33 unobserved variables that fall below the last line of models, which 
received the minimum attention. 
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Figure 27. Heatmap of mouse activity on patient prognosis screen 
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Figure 28. Attention heat map of patient prognosis screen 
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3.2.4 Discussion 
The myCORA user interface was shown to be visually appealing but with issues in 
usability and model content. Main areas of use-issues were the sorting options for variables, 
movement of variables from un-observed to observed columns, and entering information for 
dependent variables. Main issues for models were lack of information about the legend labels, 
survival prognosis and use of SHFM, interpretation of static/in development models. 
Analysis of mouse movement and attention indicated a focus on survival at the most 
important information, with little attention on options at the top and bottom of each page. Ways 
to minimize the amount of scrolling necessary to view and enter information should be explored.   
The optimal time in patient disease progression to initiate use of myCORA is difficult to 
pin down and may vary from user to user. In this pilot, the participant wanted to use CORA to 
evaluate less sick patients, with the reasoning that very sick patients would receive an LVAD 
because there is no other treatment option. This is in contrast with feedback from collaborators 
who indicated they would want to use this tool to convince very sick patients that an LVAD 
would not be beneficial and to pursue palliative care instead. For the development of the larger 
user testing, a visual of patient disease progression will be incorporated to allow users to more 
easily conceptualized and indicate when they think the tool would be of most interest. 
Overall tool use improved over time, with speed of actions improving and the participants 
knowing where to look for information. This pilot did not include using a ‘quick start’ guide or 
any educational information about the tool prior to the exercises. Introduction of a quick start 
guide or educational videos will be included for the large user testing to speed up the process of 
learning and comfort with the support tool.  
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To be confident with the model predictions, the participant indicated that she needed 
more information about the model and its performance. Future work will include validation of 
the model on each collaborating site’s specific data (as performed with patient data from 
Allegheny General Hospital.) A question for the user feedback survey will be added to ask what 
evidence they would want to see to feel confident using the prognostic tools.  
Though the myCORA online application has sections beyond prognosis, the main focus 
of the user was on the prognosis screen, which is the landing page after patient selection. 
Additional work will be needed to assess the utility of the other myCORA components (History, 
Treatment, and Workplan.) 
The user in the pilot testing was familiar with the Bayesian modeling used to derive the 
prognostic results and receives financial support from the CORA grant. Her feedback may be 
positively biased given her familiarity and involvement with the CORA research project. 
However, she may also have spoken more freely given her familiarity with the interviewer. 
Results from this pilot trial will not be included with the following user exercise testing but 
instead will be used to inform and clarify the user exercise prompt. 
3.2.5 Conclusion 
The myCORA user interface for physicians has a pleasant visual layout but needs to be 
improved in terms of usability. In terms of content, models need more information about their 
derivation and the information being presented. MyCORA has promise to be a useful tool in 
physician decision making, pending layout and content improvements, and may be used in 
multiple points in the patient disease progression. Future work includes generating feedback 
from a larger audience and validating models with data from collaborating clinical sites. 
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4.0  AIM 3: KEY FEATURES OF PATIENT BEHAVIOR IN CONTEXT OF 
MEDICAL DECISION MAKING 
4.1 FACTORS AFFECTING HEALTHCARE ENGAGEMENT BY PATIENTS WITH 
SEVERE HEART FAILURE: AN INVESTIGATION USING MACHINE LEARNING 
ABSTRACT 
Background: The decision to receive a durable left ventricular assist device (LVAD) to 
treat end stage heart failure involves understanding and weighing the risks and benefits of a 
highly invasive treatment strategy. These patients may have experienced a long, slow decline in 
health leading up to their first contemplation of receiving an LVAD. Consequently, they may 
exhibit a spectrum of cognitive impairment. Decision support tools can potentially help these 
unique patients with the LVAD decision process, but the content and presentation of information 
should be tailored to effectively engage these patients.  
Methods and Results: A survey study of 57 heart failure patients was performed to 
understand their attitudes towards their health care engagement, measured by: their medical 
knowledge, interaction with physicians, confidence with technology and data visualization, and 
questions they have about their health. The survey responses were analyzed using traditional 
descriptive statistics and machine learning (Bayesian search, k-means clustering, and latent 
dirichlet allocation text analysis). Descriptive statistics showed a positive patient response to 
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health engagement (65%, n=37 satisfied with their involvement), interest in accessing their 
health record (74%, n=42) and using a prognostic tool (56%, n=32). Machine learning identified 
a strong relationship between the patients’ numeracy and their interest in participating in their 
healthcare decisions. Text analysis of an open-ended question indicated an interest in education 
about the technical details of the LVAD (26%, n=15), a desire for personalized survival 
information (21%, n=12), and hesitancy to discuss their healthcare wants aloud with a non-
physician staff person (25%, n=14).  
Conclusions: While most patients reported interest in engaging in their healthcare, there 
was a subset of patients who were less interested in engaging in their own treatment decisions 
and less confident in understanding both health information and data visualizations. Design of a 
decision support tool for LVAD patients should consider a spectrum of ability and desire to 
understand health information and data visualization. 
4.1.1 Introduction 
Shared decision making between patients and their healthcare provider is a well-
recognized goal throughout healthcare [6, 103, 104]. It is especially important in situations where 
the consequences of treatment decisions are complicated, uncertain and severe [105]. An 
example of such a scenario is the patient’s decision to receive a durable left ventricular assist 
device (LVAD) - a decision that involves a highly invasive treatment strategy with complex 
trade-offs that affect patient survival and quality of life over an extended time. 
 
LVAD therapy is one of the limited treatment options for patients with end-stage heart 
failure. Initially used to bridge patients to a heart transplant, LVADs are now also offered as a 
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destination therapy to patients who are ineligible for a transplant. Use of an LVAD can extend 
survival and increase quality of life [7, 8], but also requires significant changes in daily life as 
well as investment of time and money from the patient and their caregiver, and presents a 
heightened risk of severe adverse events such as stroke and infection [9]. Accordingly, 
multidisciplinary heart failure teams cooperate in educating prospective LVAD candidates and 
their caregivers on the associated risks, responsibilities and lifestyle changes as they are 
discerning their treatment options [18]. Clinical decision aids can facilitate patient and caregiver 
education and decision making in this process. Many decision aids have been designed to guide 
patients throughout the progression of heart failure, including preventative care[106], 
management acute chest pain[107], and durable implanted devices such as cardiac 
defibrillator[108] and LVAD therapy[109]. Information may be shared in multiple formats, 
including printed brochures, online text, graphics, videos [110], or combinations thereof [34, 
109]. Risks are commonly conveyed to patients as percentages or probabilities [111, 112]. The 
format for presenting this information must be carefully considered, as it is important to provide 
a complete and interpretable picture of both the risks and benefits while not overwhelming a 
patient [111, 113]. Risk information is commonly presented as average probabilities for 
aggregate populations. However, recent advances in machine learning and data mining, in 
combination with the growth of clinical data registries, have made it possible to develop patient-
specific prognostic models. Our group has used these methods to develop personalized models 
for predicting LVAD outcomes, including mortality [36], and adverse events [38] [39].  
 
The goal of this study was to understand these patients’ attitudes toward their 
engagement with health information and medical decision making. While patient response to 
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various data and risk presentation methods has been extensively studied [111, 114-116] and 
patient-physician relationships have been explored [117, 118], this study explores the interaction 
of both domains in the end-stage heart failure patient population. The unique features of this 
patient population is that they are typically suffering a long, slow disease progression that leaves 
them physically and emotionally exhausted by the time of LVAD decision making[17]. They 
may also be cognitively impaired from their disease[119]. The results of this study are intended 
to inform the design of the first personalized prognostic decision aid for patients considering 
LVAD therapy.  
4.1.2 Methods 
A paper-based survey was developed by researchers at Carnegie Mellon University 
(CMU) that included domains related to: interaction with their cardiologist, interest and comfort 
with medical information related to their condition, and familiarity with visualization of 
quantitative data. (The survey is included in the Appendix, as supplemental material.) The survey 
protocol was approved by the institutional review boards (IRB) at CMU, Duke University, and 
Allegheny General Hospital. All study participants provided written informed consent and were 
not compensated for participating in the study. 
 
Patient Cohort and Data Collection 
Patients were enrolled at Duke University Medical Center (n=22) and Allegheny General 
Hospital (n=35) between May 2015 and April 2016. Patients referred to the advanced heart 
failure program in the outpatient setting for LVAD evaluation (either bridge-to-transplant or 
destination therapy) who were age ≥ 18 years and New York Heart Association (NYHA) class II 
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– IV were included. Pediatric patients < 18 years and those unable to provide consent due to 
mental or physical inability were excluded. Surveys were either conducted by a study 
coordinator (n=35) or by the patient themselves in a private setting on the hospital premises 
(n=22), prior to the patient’s clinic visit. All patients who began the survey study made it to 
completion (n = 57).  
 
Descriptive Analysis 
Descriptive statistics were compiled and analyzed in Microsoft Excel and SPSS.  
 
Free-text response analysis 
To discover common themes among responses to the final, free-text question: “If you 
could imagine a computer wizard that could answer all your questions, what would you ask?” 
we used the Latent Dirichlet Allocation (LDA) algorithm [120]. LDA is an unsupervised 
probabilistic graphical model for topic discovery. This model can be used to cluster a set of 
documents into groups that discuss a common topic. We used the Python implementation of 
LDA provided by gensim (RaRe Technologies) to analyze the responses. We performed LDA for 
5000 iterations, determining the number of iterations by computing the difference in topic 
distribution after each iteration and stopping the algorithm when the difference became 
negligible. The number of topics was chosen by generating groups with LDA for 2, 3 and 4 
topics, then assessing the coherency of the results for each group. Starting with the 4-topic LDA 
model, we found that distributions for most responses (45 out of 57) were captured entirely by 
topics 1 through 3, and the remaining responses contained a negligible proportion (of the order of 
10-16) of topic 4. This indicated that the distribution of the responses could be captured 
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effectively with less than four topics. When testing the 2-topic model, manual inspection showed 
that related documents were not clustered. For example, question responses “How long will I live 
and what can I do?” and “Survival rate of heart transplant post heart transplant and lifestyles”, 
which both are related to survival, were sorted into two different topics. The first response 
contained a high proportion of topic 2 (0.89) while the second one contained a high proportion of 
topic 1 (0.93). When using a 3-topic model, these responses were classified into the same topic. 
Thus, we concluded that the LDA model with 3 topics was the best performing model and was 
used for this analysis. In addition, we manually coded a fourth group of responses that were not 
captured by LDA, which were either blank or entered as “No”. 
 
Bayesian Analysis 
Survey data was analyzed by a Bayesian Search method using GeNie 2.1 Academic 
(Bayes Fusion, Pittsburgh, PA). Missing data elements were classified in their own category, 
missing, and were not imputed. Model background knowledge was organized such that follow-up 
or dependent survey questions were secondary to initial or stand-alone questions. The number of 
inter-dependencies between variables (nodes) was limited to 20, and the number of parent nodes 
was limited to 8. The network structure was learned over 20 iterations, with a sensitivity of 10% 
and a prior link probability of 0.1%. Results were visualized as a directional nodal network, with 
the arcs between nodes representing the influence between responses, the arc pointing to the 
dependent variable, and their thickness indicating the strength of the association [121]. Variables 
without any relationships were shown as nodes without any arcs. 
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Cluster Analysis  
Cluster analysis was performed on the dataset by assigning a numeric value to each 
answer response for the related questions identified by the Bayesian Search method. Distances 
between responses were computed using the mean absolute difference, which were then negated 
to produce a symmetric matrix of patient response similarities. Kernel Principal Components 
Analysis (kPCA) was then applied, using the similarity matrix as the kernel, to find a two-
dimensional distribution of responses [122]. This was visualized by producing a series of scatter 
plots, in which the responses to questions were encoded by a color scale.  
4.1.3 Results 
We surveyed 57 patients using a 44-item questionnaire. Patients were 82% male, 
predominantly NYHA class III, with an average age of 60 (range 29-79). The respondent cohort 
is summarized in Table 14.  
 
Table 14. Patient demographics 
Total Patients, n = 57   n Percent 
Gender Male 47 82% 
NYHA Class I 0 0% 
  II 8 14% 
 III 28 49% 
  IV 20 35% 
Age Range 25-78  
  Mean 60   
Administered by Self 22 39% 
 Research Coordinator 35 61% 
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Medical Knowledge and Interaction 
Responses related to medical knowledge and interaction are summarized in Table 15.  
Most respondents (61%) reported being at least somewhat familiar with LVADs, thought 
their condition was severe enough to need a heart transplant (77%), and would accept one (93%). 
Most patients (89%) knew their cardiologist, felt comfortable discussing their physical and 
emotional state with their medical team, preferred communicating with their doctor in person, 
but would use an email or message system if it was available. When interacting with their doctor, 
most (74%) reported spending over 60 minutes talking about their condition and were satisfied 
with the duration of their interaction. In terms of learning more about their health, most (74%) 
patients expressed the desire to view their medical records but had not requested to see them. 
The majority of patients (65%) reported feeling that they had control over their treatment 
options. 
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Table 15. Answers to Medical Knowledge and Interaction questions 
How familiar are you with VADs? n Percent 
Never heard of them 4 7% 
Somewhat familiar  33 61% 
Very familiar 17 31% 
Do you think your condition is so severe that you need a heart transplant?   
Yes 44 77% 
No 13 23% 
Would you accept a heart transplant?   
Yes 53 93% 
No 4 7% 
Do you know your HF cardiologist?   
Yes 50 89% 
Yes, but forgot their name 4 7% 
No 2 4% 
Do you feel comfortable discussing your physical and emotional state with your 
physicians? 
  
I am comfortable discussing both my physical and emotional state 50 89% 
I am comfortable discussing my physical condition, but not my feelings or emotions 4 7% 
I am generally uncomfortable asking questions about my physical and emotional 
state 
2 4% 
Which method makes you feel most comfortable asking questions of your doctor?   
In person 50 88% 
Over the phone 5 9% 
Text message 2 4% 
If you could communicate with your medical team using either an email or 
messaging system, would you consider using it? 
  
Yes 33 58% 
Maybe 12 21% 
No 12 21% 
About how much total time have you spent speaking with your doctor about your 
condition? 
  
Less than 15 min 2 4% 
15-30 min 7 12% 
30-60 min 6 11% 
Over 60 min 42 74% 
Do you feel you spent adequate time, or wish you could spend more with your 
doctor? 
  
I am satisfied 40 71% 
I was satisfied at first, but later remembered questions I wish I asked 3 5% 
I was not able to ask all the questions of my doctor, but the staff (nurses, 
coordinators, etc.) were able to fill in my missing questions 
6 11% 
I was not able to ask all the questions of my doctor, but the staff (nurses, 
coordinators, etc.) were able to fill in my missing questions 
 
 
7 13% 
 100 
Table 15 (continued). 
If you had access to your electronic health records, would you look at them and 
try to understand it? 
  
Yes, I am eager to look at my records 42 74% 
No, I am not really interested in my records 4 7% 
No, I don't think I would understand my records 8 14% 
No – “I don’t want to know” 3 5% 
Have you ever requested access to your medical records?   
Yes, very informative 8 14% 
Yes, but couldn't understand them 4 7% 
No, used a chart (myChart) 2 4% 
No 43 75% 
Which of the following best describes how you feel about your involvement in 
your treatment? 
  
I feel like I have control over what treatments I received and when 37 65% 
I have no say whatsoever, the doctors just do what they want and never ask me 3 5% 
I feel like I'm *too involved*… the doctors can't make decisions on their own, 
without asking me 
1 2% 
None of the above 16 28% 
 
Technology and Visualization Preferences 
Responses related to technology and data visualization are summarized in Table 16. 
Many patients (46%) used a smartphone and/or a computer every day (44%), and most (54%) did 
not use a tablet at all. Most patients were comfortable understanding bar graphs (63%), line 
graphs (61%), and pie charts (71%). Few patients (40%) were confident interpreting survival 
curves. While most patients (68%) had not used a decision support tool in any context, most 
thought a roadmap of their healthcare progression would be useful (53%). They also believed 
that a website or computer program with their prognosis would be useful (57%) and were 
interested in accessing videos of patients telling stories of their implant experiences (65%). 
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Table 16. Answers to Technology and Visualization Preference Questions 
How frequently do you use you a smart phone? n Percent 
Every day 26 46% 
Occasionally 9 16% 
Never 22 39% 
How frequently do you use a computer? 
  Every day 23 44% 
Occasionally 14 27% 
Never 15 29% 
How frequently do you use a tablet? 
  Every day 14 27% 
Occasionally 10 19% 
Never 28 54% 
How comfortable are you understanding Bar Graphs? 
  Not at all 10 18% 
Somewhat 11 20% 
Very 35 63% 
How comfortable are you understanding Line Graphs? 
  Not at all 9 16% 
Somewhat 13 23% 
Very 34 61% 
How comfortable are you understanding Pie Charts? 
  Not at all 7 13% 
Somewhat 9 16% 
Very 40 71% 
How comfortable are you understanding Survival Charts? 
  Not at all 16 29% 
Somewhat 17 31% 
Very 22 40% 
Have you ever used a decision tool? 
  Yes 17 32% 
No 36 68% 
If you were given a roadmap that shows the progression of your health, and the 
decision points in your care, would you find it useful?   
Yes 30 53% 
Somewhat 13 23% 
Not at all 14 25% 
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Table 16 (continued). 
If there was a website or computer program that would show your prognosis, 
would that be useful? 
  Yes 32 57% 
Somewhat 15 27% 
Not at all 9 16% 
If there was a website where you could watch short videos of other patients like 
you telling stories of their experiences, would that interest you?   
Yes 37 65% 
Somewhat 7 12% 
Not at all 13 23% 
 
Free-text response analysis with LDA 
In response to the question: “If you could imagine a computer wizard that could answer 
all your questions, what would you ask?”, the LDA model detected three topics from the data, 
exclusive of those who chose not to respond: 1) survival, longevity, 2) Non-LVAD heart failure 
treatment and prevention, and 3) LVAD outcomes and side effects. Of the 57 respondents, 19 
gave responses categorized in Topic 4: either blank, “No”, “Nothing”, or “N/A” (Table 17). 
 
Table 17. Responses to free text question, “If you could imagine a computer wizard that could answer all 
your questions, what would you ask?” 
Topic N Example responses 
1. Survival, longevity 12 “Is this (LVAD) worth the risk, will I have a longer life?” 
“How long can I live without a heart transplant?” 
“How long will I live and what can I do?” 
2. Non-LVAD Heart 
Failure Treatment and 
prevention 
11 “What is the average time one with my health usually stays on 
milrinone? What is the likelihood someone with my health will 
receive a heart for transplant in that time?” 
“Overview multiple courses of possible treatment at each stage and 
have all info in one place when making decisions” 
3. LVAD Outcomes 
and side effects 
15 “How big is the equipment? How do you shower with it?” 
“Outcome of patients similar in age with heart disease” 
“What are the side effects [of the LVAD]?” 
4. No answer 19  
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The majority of completed responses included specific details about the LVAD, risks, 
and side effects.  
 
Bayesian Search Results 
Bayesian analysis revealed several variables to be inter-related. (See Figure 29.) The 
probability of requesting medical records was positively related to comfort talking with their 
physician. The time spent with physician was positively correlated with ability to understand 
visualization of data. Interestingly, satisfaction with the time spent with the physician was not 
associated with the amount of time spent with physician. Finally, patients less comfortable 
discussing their emotional and/or physical health with their physicians were less likely to be 
interested in accessing their electronic healthcare records. 
 
 104 
 
 
 
Figure 29. Bayesian model of patient responses. Each question in the survey is represented by a node. The 
arcs between nodes represent the influence between responses to these questions; and their thickness indicates the 
strength of the association. Arc direction indicates the directionality of the relationship, with the arc pointing at the 
dependent node. Unconnected variables (bottom) were not shown to be related to any other variable. 
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Cluster Analysis  
Patients were compared by their responses to the interconnected nodes shown in Figure 
29 as well as three independent variables (age, gender, and NYHA class). Their clustering by 
answer response is shown in Figure 30. Each point is a patient and the color for each point 
indicates the patient’s response to the survey question. Interpretation was performed by visually 
noting clustering of similar responses.  
 
 
Figure 30. Cluster analysis of patient responses. Each point is one patient, plotted on a unit-less 2D space. 
The color of each dot corresponds to the patient’s answer to the question indicated in the title of each chart. 
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Clustering shows a clear delineation with patient response to data visualization. (See 
bottom row of Figure 30.) Patients who reported they understood the visualization method 
(yellow dots) cluster on the left of each plot; and patients who reported not understanding the 
visualization cluster on the right (purple dots). This is seen in all four data visualization plots. 
The right-hand cluster of patients (those who did not understand the visualizations) is also seen 
in the chart answering: “Have you requested to see your EHR?” (View_EHR) as those who had 
difficulty understanding their medical records in the past. This overlap of responses indicates that 
the patients who had not understood their EHR were the same patients who did not understand 
data visualizations. 
4.1.4 Discussion 
This study provides insight into the attitudes of advanced heart failure patients towards 
engagement with their health care, with the goal of informing the development of a patient 
decision aid that will benefit all potential LVAD patients. The information gained from the 
descriptive analysis represents an optimistic outlook, with most patients comfortable discussing 
their health with their doctors (89%), participating in and satisfied with their treatment decisions 
(65%), and interested in accessing more information to help make their decisions (74%). 
However, there is a non-negligible minority that does not fit this outlook. To better understand 
this patient set, we employed machine learning techniques. In this way, we uncover possible 
relationships that can inform the design of decision support tools to encourage all patients to 
engage in their healthcare decision making.  
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The patients who were less interested in healthcare engagement tended to spend less than 
60 minutes (cumulative) speaking with their physicians, self-identified as being less comfortable 
discussing their health with physicians and were less confident in understanding graphs and their 
own medical records. Engaging these patients in decision making requires understanding and 
addressing the underlying issues and concerns. Interestingly, in this study patient age, gender, 
and NYHA status were not associated with patient attitude towards their healthcare engagement. 
Socioeconomic status has also been suggested as a predictor of patient engagement [123, 124], 
but was not captured in this study. 
 
The results of both the Bayesian search and clustering analysis indicate numeracy, 
captured in this study as comfort interpreting different types of graphs, as the key feature 
connected to a discomfort or disinterest in health engagement. The relationship between 
numeracy and health engagement in this study is consistent with a prior finding with cancer 
patients in which overall health engagement was correlated with highest level of patient 
education [125]. It is also consistent with a study of subjective patient numeracy and satisfaction 
with physician communication, which found and inverse relationship between the two [126]. 
Therefore, patient numeracy and education level are important considerations when presenting 
health information to patients.  
 
The consequence of failing to assure understandability of health data is illustrated by the 
relationship between patient interest in seeing their medical records and whether they had asked 
to see their records previously. Patients who had previously asked for their records but could not 
understand them (7%) indicated little interest in health engagement (47% were uninterested 
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compared to 12% for patients who had not viewed their records and 4% for patients who had 
viewed and understood them). Patients may feel discouraged from not understanding their health 
information and therefore being less likely to try to engage again.  
 
Text analysis showed patients’ desire for information on the technical components of the 
LVAD and a desire for personalized outcomes, primarily survival. The first topic is a part of 
patient education, which can be effectively delivered through a decision support tool [34, 109]. 
The second topic, of personalized predictions, is being addressed by our research group through 
the development of personalized mortality predictions [36].  
 
An interesting finding of this study was that patients may be less likely to answer 
questions about their wants when asked aloud, as opposed to writing them down anonymously. 
Of the 19 patients who did not respond to the open-ended survey question, only 5 (23% of 22) 
had self-administrated the survey versus 14 (56% of 35) patients who had the survey 
administered by a research coordinator. This suggests that patients were not comfortable 
verbalizing their desire to know more about their condition or were not comfortable telling 
someone in a clinical setting. A support tool that can be viewed and interacted privately by the 
patient may provide an opportunity for engagement when patients may otherwise feel 
uncomfortable. Examples of treatment success with a non-human interaction have been seen in 
the mental health space: with  the use artificial intelligence to provide therapy to patients with 
PTSD [127] and use of a chatbot with college students dealing with depression [128].  
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When responding to questions about their current and potential use of technology, 
patients in this study indicated that they would find a computer program with their prognosis 
useful (57%) and were interested in viewing a hypothetical website with videos of patients 
talking about their experiences (65%). This is encouraging for use of advanced technology in 
patient education but cannot be used as evidence alone to eschew the more traditional hardcopy 
decision support information they currently receive. Future work needs to compare various 
education options with patients to determine the best delivery method for the most relevant 
information related to their healthcare decisions.  
 
Most patients who took this survey expressed a positive outlook on their healthcare 
engagement. However, because the trigger for the survey was attending the informational 
discussion with their physician, the sampling for this survey study may be biased toward 
healthier and better communicating patients.  
4.1.5 Conclusion 
The results of this study will inform future development of a decision aid for patients 
considering an LVAD. The heart failure patients participating in this study who had not 
understood their health information in the past or who had poor numeracy indicated low interest 
in, or comfort with, healthcare engagement. Therefore, the decision support tool should aim to 
accommodate patients at their educational and comfort level, to encourage them to face daunting 
decisions and to create a safe space to record their worries or questions. 
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4.2 PROGNOSTIC DATA LITERACY AND EFFECT ON RISK PERCEPTION IN 
GENERAL AND PATIENT POPULATIONS 
4.2.1 Introduction 
Patient decision making relies on patient and caregiver understanding of potential risks 
weighed against the benefits of treatment. For a patient considering a left ventricular assist 
device (LVAD), a major trade-off is the risk of adverse events versus increased longevity and 
quality of life [7, 8]. Decision support tools can help navigate this decision making through 
presentation of educational and statistical risk information [34, 109]. 
With improvements in data analysis techniques, personalized risk predictions are being 
developed for use in decision support tools. This adds a new layer of information for patients and 
their caregivers to process: what is their personal risk as opposed to the average patient risk. 
However, it is unknown how this individualized information will affect the patient’s overall 
perception of the risk of receiving an LVAD.  
How to present risk data and probabilities to a patient population has been extensively 
studied [111, 112], with recommendations for the combination of both visual and numeric 
information, use of probabilities instead of percentages, and careful choice of probability 
denominators. However, these studies are focused on general risk information, and do not 
directly address the issue of personalized risk information communication. Additionally, the 
differences in perception of medical risk information between patients and non-patients have not 
been fully elucidated.  
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In this study we compare the responses from a general population and a heart failure 
patient population to see if there differences in response to visualization of risk information. The 
goal is to design a decision support tool with personalized risk information that is easy to 
interpret and effective for both patients and their caregivers. To achieve this, this study has three 
aims: first, compare different visualizations of risk information for ease of interpretation; second, 
examine the effect data visualization on risk perception of using general and personalized risk 
information; and third to understand how people interpret dependent risks, such as adverse event 
risk in the context of survival probability. Differences between patient and general population 
responses will be analyzed for all three aims. 
4.2.2 Methods 
All analysis performed in this study was approved by the CMU IRB board as an exempt 
study.  
Participants 
In this study, we recruited respondents from Prolific Academic, an online community of 
questionnaire takers geared toward research studies. The general population recruitment was 
limited to English speakers over the age of 40 at the time of taking the survey. The patient 
population recruitment was limited to English speakers who self-reported a diagnosis of heart 
failure from a medical doctor. Respondents were each paid $1.50 for completing the survey 
exercise. 
The percentage of general population respondents who gave valid, complete surveys was 
130 out of 136. Participants were excluded for not finishing the survey or timing out of the 
survey (taking over 25 minutes to complete). Of the patient respondents, 3 were excluded out of 
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the 80 responses due to contradictory self-reporting about their health status (e.g., “Yes, I have 
heart failure” and “No, I do not have heart failure”. Two patients were excluded for not 
completing or timing out of the survey. 
Ease of interpretation of risk information 
Respondents were presented with risk information about having a surgery to cure a 
slowly progressing but deadly disease and then asked questions about the risks of the surgery. 
Questions measured accuracy of data interpretation as well as perception of risk.. 
Visualizations  
Respondents were randomized to viewing one of three types of visualizations (line, bar, 
or pictograph) with two types of information presented initially (average survival and average 
adverse event (AE) information or just average survival alone) and one of two types of a 
personalized survival probability reveal (above or below the average survival probability by 6%). 
With these levels, there are 12 possible types of visualizations seen by respondents.   
These three methods of displaying data were chosen based on their use in current and 
developing decision support tools. The myCORA physician decision support tool uses line 
graphs to show physicians the changing patient risks over time. The PCORI-funded LVAD 
patient decision support tool at UC Denver uses pictographs to convey risk information [109]. 
Bar graphs were included because of the high reporting of patient understanding in the CORA 
patient survey study, and the frequent reporting of bar graphs being most easily understood and 
preferred by users in the literature [129]. 
Visuals were developed by a professional designer, keeping the color scheme, font sizes, 
and textual information displayed consistent from visual to visual. Data used for the visual is 
roughly based on average risk information for patients receiving an LVAD [7]. Figure 31 has 
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examples of the three visual types, with and without AE information displayed, before and after 
the personal survival reveal. All images are scaled to half the size respondents would see on their 
computer. 
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Example one: Line graph with survival and risk of AE, with reveal of personalized survival 
probability better than average. 
                     
 
Example two: Bar graph with survival, no AE information, with reveal of personalized survival 
probability worse than average. 
 
 
Example three: Pictograph with survival and AE, with reveal of personalized survival probability 
worse than average. 
 
Figure 31. Examples of visualizations before and after personalized survival reveal 
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Time to answer 
The amount of time in seconds to complete each section was recorded and reported for 
analysis as time per question. Normalization to the number of questions was done to account for 
different sets of questions with and without AE risk and before and after the personalized 
information reveal (Table 18).  
 
Table 18. Number of questions for each participant group and section 
Information seen Number of questions 
Before reveal: Average survival and AE risk 6 
Before reveal: Average survival only 3 
After reveal: Personalized survival with average 
survival and AE risk 
5 
After reveal: Personalized survival with average 
survival 
3 
 
Time was recorded by time to submit for an entire section. Optional comments sections 
were not included in this time recording. 
Time to answer was analyzed by one-way ANOVAs to compare the amount of time taken 
by visualization type and by whether AE information was presented. A two-way ANOVA was 
performed to measure the interaction between visual and AE information. Mean +/- 1 standard 
deviation was used to report the data. 
Accuracy of interpretation 
Interpretation questions were used to measure the ability of the participant to correctly 
infer data from the graph. Three different types of questions were used: 1) Direct reporting: “Out 
of 100 people who have the surgery, how many will have an adverse event by 1 year?”, where 
participants needed to state the percent AE shown on the graph; 2) Reporting the inverse: “Out of 
100 people, how many will have died by one year?”, where participants needed to subtract the 
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percent survival from 100% to get the mortality number; and 3) Interpreting the adverse event 
and survival information together: “What is the probability of being alive without an adverse 
event by one year?” With this question type, participants needed to subtract the percentage of 
patients with AE from the percentage of survival.  
Participants who did not see AE data were only asked question type #2. Participants who 
did see adverse event data were asked question types #1 & #3 before the personalized 
information reveal and asked question type #3 again after the personalized prognosis reveal.  
The wording of the questions used two different styles: probabilistic (out of 100) and 
percentage-based (%). Question type #1 and 2 were probabilistic, while question type #3 was 
percentage-based. 
A correct answer was determined if the response was within +/- 3 of the intended 
response, to allow for small math errors. A correct answer was assigned a ‘1’ and an incorrect 
answer was assigned at ‘2’. Accuracy was measured by Mann Whitney-U comparison of 
distributions for analysis between two groups and the Kruskal-Wallace comparison of 
distribution between 3 groups. Percent of population correct was used to report the summary 
data. 
Effect of risk presentation on risk perception  
Perception of risk was measured by asking the respondents to rank the size of the risk of 
dying before one year, the likelihood of having an adverse event within one year, and the 
willingness to the surgery, each on a scale of 0 to 10.  
Analysis of responses between two groups was performed in SPSS using the Mann 
Whitney-U comparison of distributions for analysis between two groups and the Kruskal-
Wallace comparison of distribution between 3 groups. Data was visualized as the percentage of 
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respondents indicating a risk per each category (0-10). Summary data was presented as the 
percent of respondents reporting a category over 5 (6 or higher). 
Effect of average versus personal risk information on risk perception  
The change in the perceived size of risk of dying within one year was measured by 
subtracting the respondent’s original risk rating from their risk rating after the personalized 
survival probability reveal. A negative risk change indicated a decrease in the size of the 
perceived risk of dying, while a positive value indicated an increased perceived risk.  
Similarly, the change in willingness to have surgery was measured by subtracting the 
original willingness rating from the rating after the personalized prognosis reveal. A negative 
outcome indicated an increased likelihood to have surgery after the information reveal, while a 
positive outcome indicated a decreased likelihood of wanting the surgery. 
Perception of personalization 
Respondents were asked to indicate how personalized the visualizations of information 
felt to them on a scale of 0 to 10, with 0 being the least personalized and 10 being the most, after 
the personal prognosis was revealed. Responses were compared using the Mann Whitney-U or 
Kruskal-Wallace comparisons of distributions, for assessing two and three groups, respectively. 
Data was reported as the percentage of respondents indicating a risk per each category (0-10). 
4.2.3 Results 
Participant Features 
The patient and general population respondents represented similar ranges of educational 
level, races, household incomes, and location types (Table 19). The patient group was 
significantly younger than the general population respondents (mean 33 years of age versus 48) 
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and had significantly fewer females (31% versus 47%). The general population had significantly 
more caretakers than the patient group.  
 
Table 19. Demographics of general and patient populations 
 
Gen Pop, n = 130 Patient, n = 75 
 
  n % n % p-value 
Mean (Std) 48 (7.7) 33 (10.4) < 0.001 
Less than high 
school degree 
2 2% 1 1% 
0.904 
High school/GED 22 17% 12 16% 0.865 
Some college 23 18% 16 21% 0.522 
Associate degree 12 9% 2 3% 0.073 
Bachelor's 36 28% 22 29% 0.803 
Master's 25 19% 19 25% 0.303 
Professional degree 3 2% 2 3% 0.873 
Doctoral 7 5% 1 1% 0.150 
Asian 3 2% 3 4% 0.490 
Black 2 2% 2 3% 0.490 
Other 1 1% 4 5% 0.041 
White 122 94% 65 87% 0.080 
White and Black 2 2% 0 0% 0.280 
Native Hawaiian 0 0% 1 1% 0.187 
Female 61 47% 23 31% 0.023 
Less than $30,000 41 32% 21 28% 0.596 
$30,000 - $59,000 50 38% 22 29% 0.187 
$60,000-$99,000 18 14% 16 21% 0.165 
$100,000-$149,000 5 4% 8 11% 0.054 
Over $150,000 16 12% 8 11% 0.726 
Rural 20 15% 7 9% 0.219 
Suburban 59 45% 24 32% 0.060 
Urban 51 39% 44 59% 0.007 
No 113 87% 60 80% 0.187 
As a caretaker 12 9% 1 1% 0.026 
As a patient 101 78% 66 88% 0.067 
As a professional 11 8% 8 11% 0.603 
No personal 
interaction 
6 5% 0 0% 
0.059 
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Ease of interpretation of risk information: Time to respond  
Comparing the time to respond per question across all the survey sections between 
patients and the general population, the patient population is significantly faster, with 15 seconds 
for patients and 22 seconds for the general population (p-value = 0.0006) (Figure 32). 
 
  
Figure 32. Time to respond by study participant type 
 
Looking at the effect of visualization type, there was no significant difference in the 
general population, but there was an effect in the patient population (p=value = 0.03), with line 
graphs (24 seconds) and pictographs (17 seconds) being significantly different (p-value = 0.026) 
(Figure 33). 
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Figure 33.Time to respond per question by participant type and visualization 
 
The response time with and without AE information was compared. The distribution of 
interpretation questions was different when AE information was presented (3 questions) 
compared to when it was not presented (1 question), therefore there may have been an effect on 
timing due to question difficulty. This was seen in the general population group, with a 
significant difference of a 17 second increase to response time when AE information was 
included (Figure 34). However, there was no statistical difference in the time to response in the 
patient group. 
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Figure 34. Time to respond by presentation of AE information and participant type 
 
Finally, the interaction of type of visualization and inclusion of AE information was 
compared within each participant group, and there were no between-subjects effects in either the 
general population (p-value = 0.99) or the patient group (p-value = 0.8). 
 
Ease of interpretation of risk information: Accuracy of interpretation 
Four questions were asked: Direct reporting, probabilistic question “Out of 100 people 
who had the surgery, how many had an adverse event by 1 year?”; Inverse reporting, 
probabilistic question, “Out of 100 people who had the surgery, how many died by 1 year?”; 
Dependent, subtraction question before the survival reveal, “If someone had this surgery, what is 
the chance they would be alive and without an adverse event at one year?”; and dependent 
subtraction question after the survival reveal, “If you had this surgery, what is the chance you 
would be alive and without an adverse event at one year?” 
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Performance between the patient and general population cohorts was not significantly 
different for any question type (Figure 35).  Overall, survey respondents did not answer the 
questions requiring interpretation of the two pieces of data together correctly. Respondents 
correctly answered the direct information from the graph the most often and were slightly worse 
at correctly answering the inverse question. 
 
 
Figure 35. Percent of respondents correctly interpreting each question type 
 
Type of visualization influenced accuracy of interpretation in both respondent 
populations. In the general population, the bar graph had a significantly higher rate of correct 
answers for the subtraction question after the personalized survival reveal (p-value = 0.043). 
Line graphs were correctly interpreted most often (but not to a significant degree) for the direct 
and inverse questions. In the patient group, pictographs had significantly higher correct 
interpretation for the direct question (p-value = 0.015), while line graphs had significantly higher 
correct interpretation for the subtraction question after the personalized survival reveal (p-value 
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= 0.032). The line graphs were the only visual to be interpreted correctly at all for the subtraction 
questions in this population.  These results are summarized in Figure 36.  
 
 
Figure 36. Percent of respondents correctly interpreting each question type by type of visualization 
 
The reveal of personalized survival information that was better or worse than average had 
no statistically significant effect on the accuracy of interpretation for either respondent group.    
In summary, questions asking for interpretation of survival and AE information at the 
same time were not easy to comprehend. For the direct and inverse reporting questions, line 
graphs where the easiest to comprehend for the general population and pictographs and bar 
graphs were easiest to interpret for the patient group. 
 
Effect of risk presentation on risk perception: Risk of dying  
After viewing the average survival information with or without AE information 
presented, the survey participants were asked to rate the size of the risk of dying within one year 
on a scale from 0 to 10, from least to most risk.  
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The patient and general populations had significantly different responses. The general 
population tended to find the risk of death smaller (35.4% over 5 on the scale of 0 to 10) than the 
patient population (52% over 5) (p-value = 0.039) (Figure 37). 
 
 
Figure 37. Comparison of size of risk of dying between general and patient populations 
 
When considering the effect of the visualization, the type of graph had no significant 
impact on the perceived risk of dying within one year for patients or the general population (p-
value = 0.556 and 0.546, respectively). There was a trend towards the general population 
perceiving the lowest risk of dying with bar charts (29.5% over 5) compared to line and 
pictographs (35.7% and 40.9% over 5, respectively) (Figure 38a). In the patient group, 
pictographs conveyed the highest risk of dying (62.5% over 5), followed by bar and line graphs 
(50% and 42.3% over 5, respectively) (Figure 38b). 
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Figure 38. General population (a) and patient population (b) perceived risk of dying by type of visual 
 
There was a statistically significant difference in perception of the risk of dying in the 
general population when AE information is included (p-value = 0.046), but not in the patient 
population (p-value = 0.278). In the general population, inclusion of the AE information 
decreased the perceived risk of dying, with 26.2% of the respondents giving a risk size over 5, 
compared to 43.5% of the respondents without AE information. This relationship was reversed 
for the patient population, with 57.9% of the patient population reporting a perceived risk of 
dying over 5 when AE information is included, compared to 45.9% without. (Figure 39) 
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Figure 39. General population (a) and patient population (b) perceived risk of dying with and without 
inclusion of AE information. 
 
 127 
After having the personalized survival information revealed, the participants were asked 
again what they perceived to be the size of the risk of dying within one year. Some participants 
saw a personal risk 6% higher than average (n = 57 for general, n = 40 for patients) and some 
saw a personal risk 6% lower than average (n = 73 for general, n = 35 for patients). This 
difference in personal risk had a significant effect on the perception of the risk of dying in both 
participant populations (p-value = 0.006 and < 0.001 for the general and patient populations, 
respectively.) In both cases the participants seeing a personal risk below average had a higher 
perceived risk of dying (42.5%, 51.4% over 5 for general and patient populations, respectively) 
(Figure 40). 
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Figure 40. General population (a) and patient population (b) perceived risk of dying after reveal of 
personalized survival above or below the average. 
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Effect of risk presentation on risk perception: Likelihood of AE  
Only respondents who saw AE information were asked about the likelihood of having an 
adverse event within one year after surgery.  
General population respondents had a significantly different distribution of response from 
patient respondents, with patient expressing a greater likelihood of having an adverse event (50% 
versus 27.9% responding over 5, p-value = 0.016) (Figure 41). This matches the pattern in the 
perceived risk of dying, where patients also indicated a higher risk than the general population. 
 
 
Figure 41. Comparison of size of risk AE occurrence between general and patient populations 
 
The type of visualization did not have a significant effect on the distribution of perceived 
AE risk in either of the participant populations (p-value = 0.338, 0.926 for general and patient 
populations, respectively.) Pictographs conveyed the highest likelihood of AE in both the patient 
and general populations, with line graphs showing the lowest risk for the general population and 
bar graphs the lowest in the patient population (Figure 44). This matches the response of patients 
and general populations to pictographs having the highest perceived risk of dying within one 
year. 
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Figure 42. General population (a) and patient population (b) perceived risk of AE by type of visual 
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Willingness to consider surgery 
There was no statistically significant difference in the distribution of responses from 
patients or the general population when asked how willing they would be to consider having the 
surgery (p-value = 0.840). There was a trend towards patients being less likely to consider 
surgery, with 78.7% over 5, compared to 82.3% for the general population. This is in line with 
the patient population expressing a higher perceived risk of death and adverse events in the year 
after surgery, compared to the general population (Figure 43). 
 
 
Figure 43. Comparison of size of willingness to consider surgery between general and patient populations 
 
The type of visualization did not have a significant effect on the distribution of perceived 
willingness to consider surgery in either of the participant populations (p-value = 0.382, 0.251 
for general and patient populations, respectively.) Bar graphs conveyed the highest likelihood of 
considering surgery in both the patient and general populations (83.3% and 86.4% over 5, 
respectively), with pictographs having the least likelihood for the general population and line 
graphs for the patient population (76.0% and 75.0% over 5, respectively (Figure 44). 
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Figure 44. General population (a) and patient population (b) perceived willingness to consider surgery by 
type of visual 
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There was no statistically significant difference in the willingness to have surgery with or 
without the AE information included in the general or patient population (p-value = 0.363, 0.234, 
respectively). In the both the patient and general population, inclusion of the AE information 
increased the likelihood of wanting surgery, with 86.8% of the patient respondents giving a 
likelihood over 5 and 83.6% of the general population respondents (Figure 45.) 
 
 
Figure 45. General population (a) and patient population (b) perceived willingness to consider surgery by 
inclusion of AE information 
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This contrasts the results from the perceived risk of dying in the patient population, 
where inclusion of AE information conveyed a higher risk of dying within one year. Despite the 
higher risk of dying perceived by patients, the willingness to have surgery is also higher. 
After having the personalized survival information revealed, the participants were asked 
again whether they would consider having the surgery. The addition of personalized risk had a 
significant effect on the willingness to consider surgery in the general population (p-value = 
0.020) (Figure 46a) but not the patient population (p-value = 0.719) (Figure 46b). In the general 
population, the participants seeing a personal survival probability below average were less likely 
to consider surgery than those seeing a higher survival (74.0% versus 78.9% over 5, 
respectively.) The patient population had the opposite trend, with a slightly higher likelihood of 
considering surgery when the survival probability was below the average (77.1% versus 75% 
over 5, respectively). 
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Figure 46. General population (a) and patient population (b) likelihood of wanting surgery after survival 
probability is shown 
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Effect of personal vs average risk information on risk perception: Change in perceived 
risk of dying within one year 
There was not a statistically significant difference in the total delta in the perceived risk 
between patients and the general population before and after the personalized information reveal. 
There was a slight trend for patients to have an increase in their risk perception compared to the 
general population (Figure 47). 
 
 
Figure 47. Comparison of change in risk of dying perception between general and patient populations 
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When considering whether the participants saw either a personalized survival probability 
that was above or below the average survival, both populations had a significant difference 
between groups. In the general population, the perceived risk dropped by a mean of 0.86 in the 
above average survival group, compared with a rise of 0.95 when the survival was worse than 
average (p-value <0.001). Similarly, in the patient population, the perceived risk dropped by a 
mean of 0.98 in the above average survival group, compared with a rise of 0.31 when the 
survival was worse than average (p-value = 0.008) (Figure 48). 
 
 
Figure 48. Comparison of change in risk of dying perception between general and patient populations, with 
survival probability above and below average 
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The effect of the type of visual on the change in perceived risk of dying within one year 
was only significant in the below average survival general population group (p-value = 0.037). 
All other groups had no significant differences.  
The trend for the general population is that with an above average survival risk, all graph 
types have a decreased risk perception, with line graphs showing the biggest decrease in risk 
(1.37) and bar graphs the least (0.44). For the below average, general population group line 
graphs also had the biggest impact on risk perception change (1.70) and pictographs had the least 
(0.21). 
For the patient population, the below average survival group had the largest change in 
risk perception with bar graphs, with an increased risk of 0.70. Interestingly, in this group the 
participants seeing a pictograph reported a decreased risk perception of 0.60. In the above 
average survival probability patient group, line graphs had the biggest decrease in risk perception 
(1.6). The pictographs had a decrease in risk of 0.56, very similar to the response to pictographs 
in the below average group (Figure 49). 
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Figure 49. Comparison of change in risk of dying perception between visualizations, with survival 
probability above and below average in general (a) and patient (b) populations 
 
Presentation or exclusion of AE information had no significant effect on the change in 
perceived risk in any respondent group. In the general and patient populations with above 
average survival probability there is a larger decrease in risk with the AE shown versus not 
shown (-0.90 with AE versus -0.81 without AE in the general population, -1.2 with AE versus -
0.75 without in patient). In the general population group with below average survival, there is a 
larger increase in risk when AE is not shown (0.68 with AE versus 1.14 without). In the patient 
population with below average survival this pattern is reversed, including AE information 
created the larger increase in risk (0.50 with AE versus 0.12 without) (Figure 50).  
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Figure 50. Comparison of change in risk of dying perception with AE information included or not 
included, with survival probability above and below average in general (a) and patient (b) populations 
 
There was no effect from the interaction of graph type and inclusion of AE information 
on the change in perceived risk of dying within one year in any of the populations, above or 
below average survival. 
 
Effect of personal vs average risk information on risk perception: Change in willingness 
to have surgery 
There was no statistical difference in the change in willingness to have surgery between 
patients and the general population before and after the personalized information reveal (Figure 
51). 
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Figure 51. Comparison of change in willingness to have surgery between general and patient populations 
 
Whether the participants saw a personalized survival probability that was above or below 
average had a significant effect on the willingness to have surgery in the general population. The 
willingness increased by a mean of 0.21 in the above average survival group, compared with a 
decrease of 0.48 when the survival was worse than average (p-value = 0.001). 
The change in the patient population group was not significant (p- value = 0.162) but 
followed the same pattern as in the general population. The willingness to have surgery increased 
by a mean of 0.28 in the above average survival group, compared with a decrease of 0.29 when 
the survival was worse than average (Figure 52). 
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Figure 52. Comparison of change in willingness to have surgery between general and patient populations 
with above and below average survival probabilities 
 
The effect of visualization was not significant in any of the respondent groups (Figure 
53). Of the above average survival general population, respondents viewing bar graphs had the 
largest increase in willingness to have surgery (0.33), followed by line graphs (0.21) and 
pictographs (0.10). In the below average survival general population, bar graphs decreased the 
willingness the least (-0.27) followed by pictographs (-0.54) and line graphs (-0.65). This 
conveys that the bar graph makes the general population feel the most optimistic about 
considering surgery. 
In the patient population, the above average survival group had a very different response 
than the above average general population group. These participants had a decrease in 
willingness to have surgery when data was viewed on a bar graph, despite having a better than 
average survival outcome (-0.29). The line graph had the largest increase in willingness to 
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consider surgery (0.60) followed by pictographs (0.56). In the below average survival patient 
population the pictograph surprisingly increased the willingness to consider surgery (0.60), while 
the line graph decreased the willingness the most (-0.80) followed by the bar graph (-0.40). 
Taken all together, patients viewing the data on pictographs have the most optimistic change in 
willingness to consider surgery, while those patients viewing bar graphs have the greatest decline 
in willingness.  
 
 
Figure 53. Comparison of change in willingness to have surgery between general and patient populations 
with above and below average survival probabilities by type of visualization 
 
Inclusion or exclusion of AE information had no significant effect on willingness to 
consider surgery in any respondent group (Figure 54). In the general populations with above 
average survival probability there is a larger increase in willingness with the AE shown (0.37) 
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versus not shown (0.04). General population respondents seeing below average survival, had a 
greater decreased in willingness to consider surgery when AE information was not included (-
0.71) versus when it was included (-0.16). Overall, the inclusion of AE information seems to 
make the general population respondents more willing to consider surgery. 
In the patient population there is even less difference in effect with and without AE 
information. Patients with above average survival had a slight increase in willingness with AE 
included (0.20) and with AE excluded (0.35). When patients saw a below average survival 
probability, they had a slight decrease in willingness to have surgery with AE (-0.22) and 
without AE (-0.35).  
 
 
Figure 54. Comparison of change in willingness to have surgery between general and patient populations 
with above and below average survival probabilities by inclusion or exclusion of AE information 
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There is no effect from the interaction of graph type and AE information included or not 
on the change in willingness to have surgery in any of the populations, above or below average 
survival. 
 
5. Perception of personalization 
There is no statisically significant difference in the personalization perceived by the 
survey respondents by population type, data visualization, inclusion of AE, or reveal of personal 
survival probability above or below the average. 
Overall patients rated the information as being more personalized than the general 
population (80% over 5 versus 70% over 5, respectively) (Figure 55).  
 
 
Figure 55. Rank of perceived personalization of information 
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In the general respondent population, the bar graph has the highest rating of 
personalization (79.5% over 5) compared to the pictograph (70%) and the line graph (59.5%). 
This relationship is the same in the patient population, with bar graphs having the highest 
personalization rating (91.7%) compared to pictographs (80.8%) and line graphs (56%) (Figure 
56). 
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Figure 56. General population (a) and patient population (b) perceived level of personalization by type of 
visual 
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When AE information is included in the visualization, general population respondents 
report that the visual seems less personalized (63.9% over 5) than when AE information is 
excluded (75.4%). The response is reversed with patient respondents; inclusion of AE 
information has a higher perception of personalization (81.6% over 5) than without (78.4%) 
(Figure 57). 
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Figure 57. General population (a) and patient population (b) perceived level of personalization by inclusion 
or exclusion of AE information 
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Finally, both the general and patient populations who were given a below average 
survival probability found the visualization to be more personalized (42.5% and 51.4% over 5, 
respectively.) When their personal survival was above average they rated personalization of the 
visual at (31.6% and 27.5% over 5, respectively) (Figure 58). 
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Figure 58. General population (a) and patient population (b) perceived level of personalization by survival 
information above or below average 
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4.2.4 Discussion 
Two metrics were used to measure the ease of interpretation of graphs: amount of time to 
answer questions and accuracy of interpretation. Patients were significantly faster at answering 
questions that the general population. This may be due to the younger overall age of the patient 
cohort than the general population. Assessment of numeracy has shown that older people (over 
55 years of age) had significantly decreased numeracy compared to people 24-54 years of age 
[130]. Comparing the type of visualizations for speed of interpretation, line graphs were 
interpreted fastest by the general population and pictographs were interpreted fastest by patients. 
In terms of accuracy, line graphs were interpreted more correctly in all cases where there was a 
significant difference. Inclusion of adverse event information did not affect accuracy of 
interpretation. Taken all together, line graphs had the greatest ease of interpretation in both 
population types.  
Questions asking for the AE and survival to be interpreted at the same time were mostly 
answered incorrectly, with no correct answers from patients looking at bar graphs or pictographs. 
Risks that should be interpreted together may need a different style of visualization, such as part-
to-whole area graphs to indicate the dependence of the two risks [129].  
Effect of visualization of perception of risk was measured by three different areas: risk of 
dying, risk of AE, and willingness to consider surgery. For the risk of dying and risk of AE, 
patient and general populations were significantly different, with the patient group expressing a 
greater perception of risk in both cases. Having experienced varying levels of the heart failure 
disease progression, this population may be more sensitive to medical risks. Type of 
visualization and inclusion of AE had no effect on the risk perception. 
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The use of comparative data after the personalized survival probability reveal influenced 
risk perception for willingness to consider surgery in the general population. This is in line with 
a study looking at comparisons between hypothetical and average risk data in a non-patient 
population showed that people seeing a higher-than-average risk were more likely to want an 
intervention [131]. Interestingly, this effect was not seen in the patient population. The lack of 
change in the patient group willingness to consider surgery, despite a difference in perceived 
risk, suggests that the desire to pursue treatment options is not prognostic-sensitive.  
Analysis from the University of Colorado on patient attitudes when considering LVAD 
implant showed that patient decision making can be characterized as either automatic, deciding 
without much consideration of the risk data, or reflective, considering the risks, benefits, and 
burden[17]. Most patients were automatic and automatic deciders all opted for receiving an 
LVAD, while reflective patients were split: some received the pump and while others declined.  
In this study, patient response mirrored the automatic deciders, where perception of risk and 
personalized survival information did not change interest in receiving an intervention. 
Risk information’s lack of impact on interest in interventions indicates that other types of 
educational materials may be needed to engage patients in decision making. This could be the 
use of patient testimonials [132], statements from physicians [133], or values clarification 
exercises [134].  Future work on development and evaluation of the myCORA patient counselor 
will explore the effect of these elements on patient risk perceptions. 
When determining which visualization was perceived as most personalized to the user, 
there was no significant different between populations, graphs types, or inclusion of AE 
information. Directionally, bar graphs were rated as being most personalized and line graphs the 
least.  
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4.2.5 Conclusion 
The goal of this study was to determine which method of visualization was most easily 
interpretable for patients and their caregivers and how different visualizations effected risk 
perception. Line graphs were the best interpreted overall and did not bias risk perception. 
Patients were more sensitive to risk data in terms of perceiving higher risks but were less 
sensitive to risk when indicating how willing they would be to have surgery. Future presentation 
of prognostic data can use line graphs to show single risk types but may need different methods 
of presentation to show dependent risks. Other types of information than risks, such as patient 
testimonials or physician recommendations, may be needed to affect patient preferences for 
treatments. 
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5.0  CONCLUSIONS 
5.1 SUMMARY 
Development of a decision support tool requires the right information, presented to the right user, 
in the right format, at the right time. Determining what constitutes the ‘right’ approach for each 
element requires extensive work in the field of not only data analysis, but also behavioral science 
and decision making, human-computer interaction, and clinical practice. In this thesis, I 
incorporate research from all these fields to develop decision support tools for both physicians 
and patients considering LVAD implantation.  
New models to predict patient survival after LVAD implant were developed with a 
current mix of patients, including BTT and DT patients on both axial and centrifugal flow 
pumps, and elucidate the factors that drive early and late mortality risk. The predictions perform 
better than current risk scores and provide users with information on which patient features 
contribute most to their survival predictions.  
Models to predict recurrent GI bleeding and ischemic stroke expand the utility of the 
physician decision support tool, supplying information on the both the most frequent and the 
deadliest patient adverse event, respectively. Both predictive models identify features of high-
risk patients, allowing physicians to consider additional evaluation for high-risk patients.  
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Presentation of model information to physicians requires an intuitive user interface that 
fits into their regular workflow. Initial pilot testing of our user interface uncovered issues with 
layout and interactive elements that I need to address. I also need to validate the model outputs in 
a site-dependent fashion to prove the model accuracy and utility for physician buy-in. 
Patient numeracy influenced patient interest in participating in decision support, 
indicating that the presentation of prognosis information is a key component to support tool 
design. Analysis of patient and general population responses to different visual tools found that 
line graphs were most universally well-interpreted for different prognostic information and did 
not bias perception of risk.  This visual will be further explored in the future for the ability to 
present multiple risks concurrently and in low-numeracy patient populations. 
 
5.2 FUTURE WORK 
There are more outcomes to model for the LVAD patient population. To improve 
throughput for model building, I have developed an automated machine learning workflow with 
my colleague, Carmen Khoo. We plan to use the new workflow to model right heart failure 
(using the latest definitions decided by INTERMACS and ISHLT), hemorrhagic stroke, renal 
failure, infection, thrombosis and late mortality (3yrs+). I will also continue to maintain and 
update the current models with new INTERMACS data as it is made available.  
In addition to predicting outcomes for patients who received an LVAD, I will create 
models for patients who did not receive mechanical support and instead were on optimal medical 
management. This is a critical aspect in providing a balanced decision tool for patients and 
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physicians, showing what the alternative treatments are. The main dataset I intend to use for this 
model development is from the ROADMAP trial[8].  
 
Content development for the patient counselor will continue, with the patient surveys 
presented in this thesis work informing the design, along with myLVAD website discussion text 
analysis, and a future patient interview study. The patient counselor will use “lite” versions of 
the predictive algorithms from Aim 1 alongside educational information sourced from the 
literature and physician interviews.  
An observational study of heart failure patients receiving treatment information from 
doctors and thinking through options for their treatment (e.g., whether to receive an LVAD) will 
be used to identify patient concerns and values during decision making. Analysis for this study 
will employ the latest in language technologies, including topic discovery and sequence analysis. 
The design goal is to create a resource that patients can access with their caregivers from home 
to follow up after discussions with their doctors.   
I will evaluate the resulting patient decision support tool for usability through a think-
aloud study with LVAD patients and their caregivers. In this study, I will observe how patients 
and their caregivers navigate through the interface and ask questions about their perceived utility 
of the tool. Following this pilot test, I plan to apply for PCORI funding to evaluate the tool with 
a prospective patient population. 
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APPENDIX 
CORATM: CARDIAC OUTCOMES RISK ASSESSMENT
A Personalized Cardiac Counselor for Optimal VAD Therapy 
Interview Questions for Patients  
Identifier # __________ 
Date: 
This survey consists of four Parts. The first part asks a few questions about you and your health; the 
second part relates to your interaction with your medical team; the third part asks about your familiarity 
with technology; and the fourth part relates to your familiarity with decision aids. This entire survey 
should take about 30 minutes. 
PART-1: About You 
1. Is this the first time you are taking this survey?  ☐ Yes ☐ No
a. if not the first time, approximately how long ago did you last take the survey?
2. What is the purpose of your visit today?
3. Do you know the diagnosis of your heart disease? How would you describe it?
4. In your opinion, how severe your medical condition? (circle one)
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a. My health is about as good as people I know my age. 
b. I have heart failure that limits the things I can do, but it’s not a major problem. 
c. I have heart failure that prevents me from doing some of the things I like to do. 
d. I have severe heart failure that might kill me eventually (a year from now.) 
e. I have severe heart failure that might prevent me from ever leaving the hospital. 
 
5. --------------------------------------------------------------------------------------------------------------------------- D
o you think your condition is so severe that you need a heart transplant? Yes / No 
6. --------------------------------------------------------------------------------------------------------------------------- I
f you were offered the option of a heart transplant, would you accept it? Yes / No 
7. How familiar are you with ventricular assist devices? (circle one) 
 
a. Never heard of them 
b. Somewhat familiar: I’ve heard of them, but not sure what they are, how they work, or what 
good they could do for me. 
c. Very familiar: I’ve read up on them and/or my doctor has told me about them and I have a 
good understanding about how they could (or could not) help me. 
 
Part 2: Interaction with your medical team. 
1. Do you know who your heart failure cardiologist is? (circle one) 
a. Yes, his / her name is __________________________ 
b. Yes, I met him / her, but I cannot remember his name. 
c. I really don’t know. 
2. Do you feel comfortable discussing your physical and emotional state with your physicians? 
a. I am comfortable discussing both my physical and emotional state 
b. I am comfortable discussing my physical condition, but not my feelings or emotions. 
c. I am generally uncomfortable asking questions about my physical and emotional state. 
3. Which of the following methods of communication makes you feel most comfortable asking 
questions from you doctor? (circle one) 
a) In person b) Over the phone c) By email 
4. If you had a safe and secure way of communicating with your medical team using either an email or 
messaging system, would you consider using it? (circle one) 
a) Yes  b) No  c) Maybe 
5. How interested are you in understanding your condition? (circle one) 
a. I am very interested in learning everything I can about my condition. 
b. I am somewhat interested. 
c. I rely on the experts who know what they are doing. 
6. Is there anything in particular you wish you knew more about? (i.e. more information to help interpret 
your test results or to better understand your treatment options) 
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7. About how much total time have you spent speaking with your doctor about your condition prior to 
taking this survey? 
a. less than 15 minutes b. 15-30 minutes c. 30-60 minutes d. over an hour 
8. Do you feel you spent adequate time, or wish you could spent more time with you doctor? 
a. I am satisfied with the time spent with my doctor. 
b. I was not able to ask all the questions of my doctor, but the staff (nurses, coordinators, etc.) 
were able to fill in my missing questions. 
c. I wish I had more time to ask questions of my doctor. 
d. I was satisfied at first, but later remembered questions I wish I had asked. 
9.  If you had access to your electronic health records, would you look at them and try to understand it?  
a. Yes, I am eager to look at my records 
b. No, I am not really interested in my records. 
c. No, I don’t think I would understand my records. 
d. No, for another reason: ____________________________________________ 
 
PART-3: Your familiarity with technology. 
8. Have you done any internet research in the past regarding your heart failure?  
a. No: Proceed to next question. 
b. Yes: we would like to know what sites you visited, and your impressions of their helpfulness 
 Did not visit Visited: not 
useful. 
Visited: useful 
WebMD ☐ ☐ ☐ 
HeartHope ☐ ☐ ☐ 
Other:______________* ☐ ☐ ☐ 
Other:______________* ☐ ☐ ☐ 
* if you cannot remember the name, you can leave this blank. 
9. If you visited one of these sites, was there any information that you were unable to find? 
 
10. Have you ever requested access to your medical records? (circle one)  
a. No. 
b. Yes, but I really could not understand the information. 
c. Yes, I found it to be informative. 
11. How frequently do you use the following electronic devices? 
 Every day Occasionally Never 
Smart phone (like iPhone) ☐ ☐ ☐ 
Computer (laptop or 
desktop) 
☐ ☐ ☐ 
Computer tablet ☐ ☐ ☐ 
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12. How comfortable are you understanding and interpreting the following types of graphs?  
 Do not understand Understand somewhat Understand well 
Bar Graph ☐ ☐ ☐ 
Line Graph ☐ ☐ ☐ 
Pie Chart ☐ ☐ ☐ 
Survival Chart ☐ ☐ ☐ 
 
Bar Graph 
 
 
Line Plot 
 
 
Pie Chart 
 
Survival Curve 
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Part 4: Decision Aids and Shared Decision Making 
13. Have you ever used a decision tool… like for buying a car or choosing a college? 
a) yes (explain) ___________________  b) no 
14. Which of the following statements best describes how you feel about your involvement in your 
treatment? 
a) I feel like I have control over what treatments I receive and when. 
b) I have no say whatsoever, the doctors just do what they want and never ask me. 
c) I feel like I’m *too involved* … the doctors can’t make a decision on their own, without 
asking me. 
d) none of the above 
15. If you were given a “roadmap” that shows the progression of your health, and the decision points in 
your care, would you find that useful? 
a. Yes, I think it would be very useful. 
b. I think it would be somewhat useful. 
c. I don’t think it would be useful for me. 
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16. If there was a website or computer program that would show your prognosis (risk of death, becoming 
more sick, or side-effects of treatment) would that be useful? 
a. Yes, I think it would be very useful. 
b. I think it would be somewhat useful. 
c. I don’t think it would be useful for me. 
 
17. If there was a website where you could watch short videos of other patients like you telling stories of 
their experiences, would that interest you? 
yes  maybe   no 
18. If you can imagine a computer “wizard” that could answer all your questions about your health, or 
your treatment choices, what would you ask? 
 
 
This concludes the survey. Thanks for your participation! 
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